Background
==========

Description of the condition
----------------------------

Malaria continues to pose a serious global health challenge despite considerable progress over the past decade to control and eliminate malaria in some parts of the world. In 2010, there were an estimated 219 million malaria illness episodes, resulting in around 660,000 deaths (WHO [@b69]).

Five species of *Plasmodium* parasite cause malaria in humans; *Plasmodium falciparum* and *P. vivax* are the most common, and *P. falciparum* causes most of the severe disease cases (WHO [@b69]). Uncomplicated malaria is the mild form of the disease, typically characterized by fever with or without associated headache, tiredness, muscle pains, abdominal pains, rigors, nausea, and vomiting (WHO [@b66]). If left untreated, uncomplicated malaria can rapidly develop into severe, life-threatening forms of the disease, particularly in people that have not acquired immunity. Effective immunity generally requires repeated infections over five to 10 years, and is reduced during pregnancy. Consequently in highly endemic settings, as seen in many areas of rural sub-Saharan Africa, young children and pregnant women are most at risk, while in settings with low or seasonal transmission, all age groups can be equally at risk (WHO [@b66]).

In many parts of the world, *P. falciparum* has developed resistance to most antimalarial drugs used as monotherapy (White [@b64]; WHO [@b67]). Consequently, the World Health Organization (WHO) now recommends that *P. falciparum* malaria is always treated with a combination of two drugs that act at different biochemical sites within the parasite (WHO [@b66]). If a parasite mutation producing drug resistance arises spontaneously during treatment, the parasite should then be killed by the partner drug, thus reducing or delaying the development of resistance and increasing the useful lifetime of the individual drugs (White [@b61]; White [@b62]).

Five artemisinin-based combination therapies (ACTs) are now recommended for the first-line treatment of uncomplicated malaria; artemether-lumefantrine (AL), artesunate plus amodiaquine (AS+AQ), artesunate plus mefloquine (AS+MQ), artesunate plus sulfadoxine-pyrimethamine (AS+SP), and dihydroartemisinin-piperaquine (DHA-P) (WHO [@b66]). The artemisinin components (artemether, artesunate, or dihydroartemisinin) are highly effective schizonticides, and over three days of treatment rapidly eliminate up to 90% of the blood stage asexual forms of *P. falciparum*. The partner drugs are longer-acting and are used to clear any residual infection (Nosten [@b50]; Kurtzhals [@b46]; WHO [@b66]). The combinations with very long half-lives (AS+MQ and DHA-P) can provide a period of post-treatment prophylaxis which may last for up to six weeks (Sinclair [@b59]).

Resistance to the artemisinin-derivatives was first reported among *P. falciparum* strains in 2008 along the Thai-Cambodian border (Dondorp [@b37]; Lim [@b47]; WHO [@b67]). This has led to global initiatives to contain the spread of artemisinin resistance, which includes the development of new drugs to partner and protect the artemisinin-derivatives in ACT (WHO [@b68]).

Description of the intervention
-------------------------------

Pyronaridine is a benzonaphthyridine derivative first synthesized in China in 1970 (Fu [@b39]). It was used extensively as a monotherapy to treat *P. falciparum* and *P. vivax* infections in the Hunan and Yunan provinces of China for more than 20 years (Chen [@b34]), and to treat *P. falciparum* in some parts of Africa during the 1980s. Between 1985 and 1995, some in vitro pyronaridine-resistant strains of *P. falciparum* emerged along the China-Lao and China-Myanmar border areas (Yang [@b70]).

Elsewhere, in vitro studies using clinical isolates of *P. falciparum* from Africa, Cambodia, and Thailand in the 1990s demonstrated high activity of pyronaridine against chloroquine-sensitive and chloroquine-resistant *P. falciparum* strains (Childs [@b35]; Basco [@b29]; Chen [@b34]; Pradines [@b51]; Ringwald [@b56]), and more recent in vitro studies have also shown pyronaridine to be effective against multiple-drug resistant *P. falciparum* schizonts and gametocytes in Thailand and Indonesia ([@b33]; Price [@b53]), and against chloroquine-resistant *P. falciparum* strains in Gabon (Kurth [@b45]). However, almost half of 28 *P. falciparum* isolates tested in vitro in Abidjan, Cote d\'Ivoire, were resistant to pyronaridine and also showed some evidence of cross resistance to dihydroartemisinin (Brice [@b31]).

Pyronaridine interferes with the glutathione-dependent detoxification of haem and targeting of β-haematin formation (Auparakittanon [@b28]). Its activity in multi-drug resistant strains of *P. falciparum* is believed to be due to its ability to inhibit P-glycoprotein function and reverse multi-drug resistance in cell lines (Qi [@b54]; Pradines [@b52]).

Pyronaridine is structurally related to amodiaquine, leading to some concerns that pyronaridine may have similar toxicity related to the formation of a reactive metabolite (quinoneimine) in the liver and white blood cells. However, some studies suggest that pyronaridine and other bis-Mannich compounds are structurally advantaged and do not form the bioactive quinoneimine metabolite (Naisbitt [@b49]; Ruscoe [@b57]).

### Assessment of antimalarial drug efficacy

The WHO recommends that new antimalarials should have a treatment failure rate of less than 5%, and that failure rates greater than 10% with existing first-line antimalarials should trigger a change in treatment policy (WHO [@b66]).

Treatment failure can be classified as:

Early treatment failure:

the development of danger signs or severe malaria on days 1, 2, or 3 in the presence of parasitaemia;parasitaemia on day 2 higher than on day 0;parasitaemia and axillary temperature = 37.5 °C on day 3;parasitaemia on day 3 = 20% of count on day 0.

Late treatment failure:

development of danger signs, or severe malaria, after day 3 with parasitaemia;presence of *P. falciparum* parasitaemia and axillary temperature = 37.5 °C on or after day 4;presence of *P. falciparum* parasitaemia after day 7.

The late reappearance of *P. falciparum* parasites in the blood of an infected person can be due to failure of the drug to completely clear the original parasite (a recrudescence) or due to a new infection, which is especially common in areas of high transmission. A molecular genotyping technique called polymerase chain reaction (PCR) can be used in clinical trials to distinguish between recrudescence and new infection, giving a clearer picture of the efficacy of the drug and its post-treatment prophylactic effect (White [@b63]; Cattamanchi [@b32]; WHO [@b65]).

The WHO recommends a minimum follow-up period of 28 days for antimalarial efficacy trials, but longer periods of follow-up may be required for antimalarials with long elimination half-lives (White [@b63]; Bloland [@b30]). Treatment failure due to true recrudescence of malaria parasites may be delayed until the drug concentration falls below the minimum concentration required to inhibit parasite multiplication, which may be beyond 28 days. The WHO recommends 42 days follow-up for trials involving lumefantrine and piperaquine and 63 days follow-up for trials of mefloquine (WHO [@b66]).

Why it is important to do this review
-------------------------------------

Early studies of pyronaridine monotherapy conducted in Africa showing efficacy against chloroquine-resistant *P. falciparum* malaria (Ringwald [@b56]), and promising dose finding studies of the artesunate-pyronaridine combination from the Gabon (Ramharter [@b24]), have led to the promotion of artesunate-pyronaridine as a possible addition to the current list of recommended ACTs (Vivas [@b60]; Croft [@b36]).

This review aims to systematically evaluate the available trials on the effectiveness and safety of artemisinin plus pyronaridine for consideration by global and national policy makers.

Objectives
==========

To evaluate the efficacy and safety of artesunate-pyronaridine compared to alternative ACTs for treating people with uncomplicated *P. falciparum* malaria.

Methods
=======

Criteria for considering studies for this review
------------------------------------------------

### Types of studies

Randomized controlled trials (RCTs).

### Types of participants

Adults and children with uncomplicated *P. falciparum* malaria, as confirmed by either microscopy or rapid diagnostic tests.

### Types of interventions

#### Intervention

Artesunate plus pyronaridine.

#### Control

WHO-recommended ACTs for treating malaria.

For an additional safety analysis we extended the inclusion criteria to all RCTs comparing pyronaridine alone or in combination with any other antimalarial.

### Types of outcome measures

We used current WHO recommendations to guide the selection of outcomes for this review (Bloland [@b30]; WHO [@b65]).

#### Primary outcomes

Total treatment failure at day 28, 42, or 63 (PCR-unadjusted and PCR-adjusted).

#### Secondary outcomes

Early treatment failureParasite clearanceFever clearanceGametocyte carriage

##### Adverse events

Serious adverse events (leading to death, requiring hospitalization or prolongation of existing hospitalization, are life threatening, or result in persistent or significant disability or incapacity)Adverse events leading to withdrawal from treatment (discontinuation of trial drug or withdrawal from trial)Patient reported symptomsAbnormal liver function tests (LFTs)Abnormal WBC countsAbnormal electrocardiogram (ECG) findings

Search methods for identification of studies
--------------------------------------------

We attempted to find all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

### Electronic searches

We updated previous literature searches done in February 2007 and August 2012 of the following databases using the search terms and strategy described in Appendix 1 up to 16 January 2014: Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL), published in *The Cochrane Library*; MEDLINE; EMBASE; and LILACS. We also searched ClinicalTrials.gov, the *meta*Register of Controlled Trials (*m*RCT) and the WHO\'s International Clinical Trials Registry Platform Search Portal for ongoing or recently completed trials using \'pyronaridine\' and \'malaria\' as search terms.

### Searching other resources

#### Conference proceedings

We searched the following conference proceedings for relevant abstracts: The American Society of Tropical Medicine and Hygiene Annual Meetings (2007, 2008, 2009, and 2010); The Third ASEAN Congress of Tropical Medicine and Parasitology (ACTMP3); the MIM Pan-African Malaria Conference (2005 and 2009); the International Congress on Infectious Diseases (ICID) (2002, 2004, 2008, and 2010); the International Conference on Malaria: 125 years of Malaria Research 2005; the Keystone Symposia Global Health Series: and Malaria (Immunology, pathogenesis and perspectives) 2008.

#### Reference lists

We checked the reference lists of all trials identified by the above methods.

#### Contacting organizations and experts

We contacted the Medicines for Malaria Venture and the WHO for information about ongoing and unpublished trials.

Data collection and analysis
----------------------------

### Selection of studies

Hasifa Bukirwa (HB) and Prathap Tharyan (PT) independently scanned the results of the search strategy and retrieved the full text articles of all potentially relevant trials, conscious of the possibility of multiple publications of the same trial. HB and PT independently assessed each potentially relevant trial for inclusion in the review using an eligibility form based on the inclusion criteria. There were no disagreements. We excluded studies that did not meet the eligibility criteria and listed the reasons for exclusion in the \'Characteristics of excluded studies\' table.

### Data extraction and management

HB and PT independently extracted the data from the trials using data extraction forms. We resolved disagreements through discussion. For dichotomous outcome measures, we recorded the number of participants experiencing the event and the number analysed in each group. For continuous outcome measures, we extracted arithmetic means and standard deviations for each group together with the numbers analysed in each group.

#### Primary outcome

Our primary analysis drew on the WHO\'s protocol for assessing and monitoring antimalarial drug efficacy (Bloland [@b30]). This protocol has been used to guide most efficacy trials since its publication in 2003, even though it was designed to assess the level of antimalarial resistance in the trial area rather than for comparative trials. As a consequence, a high number of randomized participants are excluded from the final efficacy outcome as losses to follow-up or voluntary or involuntary withdrawals (see [Table 1](#tbl1){ref-type="table"}).

##### PCR-unadjusted total failure

We calculated PCR-unadjusted total failure (*P. falciparum*) as the sum of early treatment failures and late treatment failures (without PCR adjustment). The denominator excludes participants for whom an outcome was not available (for example, those who were lost to follow-up, withdrew consent, took other antimalarials, or failed to complete treatment) and those participants who did not to fulfil the inclusion criteria after randomization.

##### PCR-adjusted total failure

We determined PCR-adjusted total failure (*P. falciparum*) as the sum of early treatment failures, and late treatment failures due to PCR-confirmed recrudescence. We treated participants with indeterminate PCR results, missing PCR results, or PCR-confirmed new infections as involuntary withdrawals and excluded them from the calculation. The denominator excludes participants for whom an outcome was not available (for example, those who were lost to follow-up, withdrew consent, took other antimalarials, or failed to complete treatment) and participants who did not fulfil the inclusion criteria after randomization.

These primary outcomes relate solely to failure due to *P. falciparum*. For both PCR-unadjusted and PCR-adjusted total failure, we retained in the calculation participants who developed *P. vivax* parasitaemia during follow-up if they were treated with chloroquine and continued to be monitored by the trialists. We classified them as treatment successes provided they did not go on to develop *P. falciparum* parasitaemia. We excluded from the calculation participants who developed *P. vivax* parasitaemia and were removed from the trial\'s follow-up at the time of *P. vivax* parasitaemia.

### Assessment of risk of bias in included studies

For efficacy outcomes we assessed the risk of bias for each included trial using the Cochrane tool for assessing the risk of bias (Higgins [@b43]). For each of six domains; sequence generation; allocation concealment; blinding of participants, trial personnel and outcome assessors; incomplete outcome data; selective reporting; and other sources of bias, we assigned a judgment regarding the risk of bias. We classified these judgments as \'high risk\', \'low risk \', or \'unclear risk\' of bias. We recorded these assessments in the standard \'risk of bias\' tables and summarized the risk of bias for each trial in a summary risk of bias graph.

For patient reported adverse events, we assessed the risk of bias by examining if monitoring was active or passive; whether participants and outcome assessors were blinded; whether the outcome data reporting was complete; whether all participants were included; and whether data analysis was independent of pharmaceutical companies ([Table 2](#tbl2){ref-type="table"}).

For laboratory reported adverse events, we assessed the risk of bias by examining which tests were performed, the timing of the tests, the completeness of reporting, and the independence of the data analysis ([Table 2](#tbl2){ref-type="table"}).

### Measures of treatment effect

We extracted data from each included trial to calculate risk ratios, 95% confidence intervals (CIs) for dichotomous data, and mean differences with 95% CIs for continuous data.

### Unit of analysis issues

We did not encounter any unit of analysis issues.

### Dealing with missing data

If data from the trial reports were insufficient, unclear, or missing, we attempted to contact the trial authors for additional information. If we considered that the missing data rendered the result uninterpretable, we excluded the data from the meta-analysis and clearly stated the reason for exclusion. We explored the potential effects of missing data through a series of sensitivity analyses ([Table 1](#tbl1){ref-type="table"}).

### Assessment of heterogeneity

We assessed heterogeneity amongst trials by inspecting the forest plots, applying the Chi² test with a 10% level of statistical significance, and also using the I² statistic with a value of 50% used to denote moderate levels of heterogeneity.

### Assessment of reporting biases

There were too few trials to examine funnel plot asymmetry for evidence of small trial effects or publication bias.

### Data synthesis

We analysed data using Review [@b55].

For the primary analysis we stratified by comparator ACT, and when outcomes were assessed and reported at different time-points, we also stratified the analyses by time point. We performed meta-analysis where appropriate after assessment and investigation of heterogeneity. In the first instance, we used a fixed-effect model and applied a random-effects model when the Chi² test P value was \< 0.1 or the I² statistic was = 50%.

Arithmetic means and standard deviations used to summarize continuous data are assumed to be normally distributed; however, sometimes these summary statistics are incorrectly used when the data are not normally distributed. Therefore, when arithmetic means were reported, we checked the normality of the data by calculating the ratio of the mean over the standard deviation. If this ratio (mean/standard) was \< 2, then it is likely that the data are skewed as the mean cannot then lie in the centre of a normal distribution. It is possible to combine data with less severe degrees of skew in meta-analyses and when ratio of the mean over the standard deviation was more than one (ratios less than one indicate that data were severely skewed), we combined data from these trials with normally distributed data.

### Subgroup analysis and investigation of heterogeneity

There were too few trials to use subgroup analyses to explore the causes of heterogeneity. However, to explore the generalizability of the evidence we subgrouped the available data by age (\< 5 years versus ≥ 5 years), country, and geographic region.

### Sensitivity analysis

We assessed that all three trials were at low risk of bias so we did not perform a sensitivity analysis exploring effects of risk of bias.

To investigate the robustness of the methodology used in the primary analysis, we conducted a series of sensitivity analyses. The aim of this was to restore the integrity of the randomization process by adding excluded groups back into the analysis in a stepwise fashion (see [Table 1](#tbl1){ref-type="table"} for details).

#### Quality of evidence

We assessed the quality of evidence across each outcome measure using the GRADE approach. The quality rating across studies has four levels: high, moderate, low, or very low. RCTs are initially categorized as high quality but can be downgraded after assessment of five criteria: risk of bias, consistency, directness, imprecision, and publication bias (Guyatt [@b41]).

Results
=======

Description of studies
----------------------

See Characteristics of included studies, and Characteristics of excluded studies sections.

### Results of the search

Of the 52 reports we retrieved by the search, we identified 39 potentially relevant reports. Three trials comparing artesunate-pyronaridine with other ACTs met the inclusion criteria for the main review (Tshefu [@b6]; Kayentao [@b1]; Rueangweerayut [@b5]). We included three additional trials for a further assessment of the effect of pyronaridine on liver function (Ringwald [@b3]; Ringwald [@b4]; Poravuth [@b2]). We described the results of the search in a flow diagram ([1](#fig01){ref-type="fig"})

![Flow diagram.](CD006404-0001-FIG01){#fig01}

### Included studies

#### Efficacy trials

The three efficacy trials were all Phase III non-inferiority trials conducted by the public-private partnership of Medicines for Malaria Venture (Switzerland) and Shin Poong Pharmaceuticals (Korea) for registration with the European Medicines Agency (Tshefu [@b6]; Kayentao [@b1]; Rueangweerayut [@b5]).

##### Artesunate-pyronaridine versus artemether-lumefantrine

Two multicentre trials that included 1807 participants evaluated this comparison (Tshefu [@b6]; Kayentao [@b1]).

Most participants (88.3%) were recruited from trial sites in Africa (Burkina Faso, Cote d\'Ivoire, Democratic Republic of Congo, Gabon, The Gambia, Ghana, Kenya, Mali, Mozambique, and Senegal), with a small number (11.7%) from Southeast Asia (Indonesia and the Phillipines). All recruiting sites were endemic for *P. falciparum* malaria and most were reported as highly endemic.

Most participants were older children or adults, and only 232 children aged under five years, and 15 aged under one year were included.

Important exclusion criteria were severe malaria, cerebral malaria, severe anaemia, pregnant and lactating women, and people with hepatic, renal, or other disorders. Tshefu [@b6] also excluded those with severe malnutrition and Kayentao [@b1] excluded children with HIV infection.

In both trials, artesunate-pyronaridine was administered once daily for three days, and artemether-lumefantrine twice daily for three days in the standard dosing (see [Table 3](#tbl3){ref-type="table"}).

##### Artesunate-pyronaridine versus artemether plus mefloquine

A single multicentre trial, enrolling 1271 participants evaluated this comparison (Rueangweerayut [@b5]).

Most participants (81.3%) were from Southeast Asia (Cambodia, India, Thailand, and Vietnam), with a smaller number (18.7%) from Africa (Burkina Faso, Ivory Coast, and Tanzania). Malaria endemicity was high in most sites.

Although the trial planned to recruit participants aged between 3 to 60 years, the youngest participant was five years old.

Important exclusion criteria were severe malaria, cerebral malaria, severe anaemia, severe malnutrition, pregnant and lactating women, and people with hepatic or renal disorders.

Both artesunate-pyronaridine and artesunate plus mefloquine were administered once daily for three days (see [Table 3](#tbl3){ref-type="table"}).

#### Additional safety trials

The three additional safety trials compared artesunate-pyronaridine versus chloroquine (Poravuth [@b2]), and pyronaridine alone versus chloroquine (Ringwald [@b3]; Ringwald [@b4]).

Poravuth [@b2] was conducted in Asia and primarily evaluated the effects of artesunate-pyronaridine on *P. vivax* malaria (Cambodia, India, Indonesia, and Thailand). Ringwald [@b3] and Ringwald [@b4] were conducted in Cameroon.

Poravuth [@b2] randomized 456 participants aged seven years to 60 years; Ringwald [@b3] randomized 96 adults aged 15 to 64 years, and Ringwald [@b4] recruited 88 children only, aged five years to 15 years.

For further details of the included trials see the \'Characteristics of included studies\' tables.

### Excluded studies

We excluded 21 trials (22 records) for the reasons described in the \'Characteristics of excluded studies\' table. In brief; 13 were not randomized, four were quasi-randomized (used alternation), and five did not have populations, comparisons, or outcomes of relevance to this review ([1](#fig01){ref-type="fig"}).

One trial comparing pyronaridine alone for three days versus dihydroartemisinin alone for seven days versus a combination of pyronaridine and dihydroartemisinin for three days did not meet the inclusion criteria for the primary efficacy analysis due to the lack of an appropriate comparison arm with an ACT, and was not included in the safety analysis as LFTs were not reported (Liu [@b17].

Risk of bias in included studies
--------------------------------

See [2](#fig02){ref-type="fig"}.

![Risk of bias summary table (Methodological quality summary): review authors\' judgements about each methodological quality item for each included trial.](CD006404-0001-FIG02){#fig02}

### Allocation

All trials were at low risk of selection bias.

### Blinding

The four non-inferiority trials were at low risk for performance and detection bias as they used double-dummy techniques, or independent outcome assessors and trial personnel who were not aware of allocation (Tshefu [@b6]; Poravuth [@b2]; Kayentao [@b1]; Rueangweerayut [@b5]).

The additional two safety trials (Ringwald [@b3]; Ringwald [@b4]) were open label or inadequately masked but were at low risk of bias, since blinding would not affect detection of the adverse outcomes sought in this review.

### Incomplete outcome data

All of the included trials reported attrition with details of all randomized participants.

### Selective reporting

Tshefu [@b6]; Poravuth [@b2]; Kayentao [@b1] and Rueangweerayut [@b5] were prospectively registered and appeared free of selective reporting, as ascertained from the data presented in the reports, the registration documents, and where available, the trial protocols.

### Other potential sources of bias

We considered that Ringwald [@b3]; Ringwald [@b4]; and Tshefu [@b6] had other potential biases (see Risk of bias tables) but the effects on these on outcomes are uncertain.

For adverse events, we conducted additional assessments of the adequacy of safety monitoring and the completeness of reporting. For patient reported adverse events, the method for monitoring adverse events was unclear in all six trials, the days monitoring occurred was unclear in five trials, and the day of outcome reporting unclear in all six trials (see [Table 4](#tbl4){ref-type="table"}). For biochemical adverse events, the frequency of testing was adequate in three trials (Tshefu [@b6]; Poravuth [@b2]; Kayentao [@b1]), and reporting was complete in two trials (Tshefu [@b6]; Poravuth [@b2]; see [Table 5](#tbl5){ref-type="table"}).

Effects of interventions
------------------------

See: **Summary of findings for the main comparison** Artesunate-pyronaridine compared to artemether-lumefantrine for uncomplicated falciparum malaria; **Summary of findings 2** Artesunate-pyronaridine compared to artesunate plus mefloquine for treating uncomplicated *P. falciparum* malaria; **Summary of findings 3** Liver toxicity of pyronaridine compared to other antimalarials

### Comparison 1. Artesunate-pyronaridine versus artemether-lumefantrine

Two trials, including 1595 participants from Africa and 212 from Southeast Asia, compared artesunate-pyronaridine with artemether-lumefantrine (Tshefu [@b6]; Kayentao [@b1]). Only Kayentao [@b1] included children aged under five years (232 children), of which only 15 were aged under one year. Follow-up was until day 42.

#### Treatment failure

At day 28, the proportion of participants with recurrent parasitaemia was lower in those treated with artesunate-pyronaridine compared to artemether-lumefantrine (PCR-unadjusted treatment failure; RR 0.60, 95% CI 0.40 to 0.90; two trials, 1720 participants, Analysis 1.1, [3](#fig03){ref-type="fig"}). However, after PCR-adjustment treatment failure, it was below 5% with both ACTs, with no differences between groups (PCR-adjusted treatment failure: two trials, 1650 participants, Analysis 1.1).
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At day 42, there were no significant differences between artesunate-pyronaridine and artemether-lumefantrine for PCR-unadjusted (two trials, 1691 participants, Analysis 1.2) or PCR-adjusted treatment failure (two trials, 1472 participants, Analysis 1.2). PCR-adjusted treatment failure with artesunate-pyronaridine was marginally above 5% in one trial at this time-point (6.8%).

Only two people on artesunate-pyronaridine and one on artemether-lumefantrine experienced early treatment failure (two trials, 1676 participants, Analysis 1.3).

#### Parasite clearance

Both trials reported that artesunate-pyronaridine cleared parasites from the peripheral blood quicker than artemether-lumefantrine. Tshefu [@b6] reported a slightly lower mean clearance time (MD 3.2 hours, 95% CI 4.38 to 2.02; one trial, 1170 participants; Analysis 1.4), and Kayentao [@b1] reported a slightly lower median clearance time (24.1 hours, 95% CI 24.0 to 24.1 with artesunate-pyronaridine versus 24.2 hours, 95% CI 24.1 to 32.0 with artemether-lumefantrine; P = 0.02, authors\' own figures, one trial, 535 participants, [Table 6](#tbl6){ref-type="table"}). These differences are probably not clinically important.

#### Fever clearance

Fever clearance times were similar between groups in both trials. Tshefu [@b6] reported mean fever clearance time as marginally shorter following treatment with artesunate-pyronaridine than artemether-lumefantrine (MD 1.2 hours, 95% CI 2.38 to 0.02 hours, one trial, 1170 participants, Analysis 1.5), while Kayentao [@b1] reported equal median clearance times (8.1 hours with artesunate-pyronaridine versus 8.1 hours with artemether-lumefantrine, P = 0.049, authors\' own figures, one trial, 535 participants, [Table 6](#tbl6){ref-type="table"}).

#### Gametocyte clearance and carriage

In Tshefu [@b6], 8% of participants given artesunate-pyronaridine and 5% of those given artemether-lumefantrine had peripheral gametocytaemia at baseline. The mean time to gametocyte clearance was 10.5 hours shorter with artesunate-pyronaridine (MD 10.5 hours, 95% CI 12.4 to 8.60; one trial, 1170 participants, Analysis 1.6).

In Kayentao [@b1], 13% of participants had gametocytes at baseline. No subsequent statistically significant differences in gametocyte carriage, or gametocyte development were reported (one trial, 532 participants, [Table 6](#tbl6){ref-type="table"}).

#### Serious adverse events

Neither trial reported any deaths. There were six serious adverse events in total with no significant difference between groups (0.3% with artesunate-pyronaridine versus 0.3% with artemether-lumefantrine; two trials, 1787 participants, Analysis 1.7).

#### Adverse events leading to withdrawal from treatment

There was no significant difference between groups in the proportion of participants withdrawn from the trial due to adverse events (2.3% with artesunate-pyronaridine versus 1.7% with artemether-lumefantrine; two trials, 1787 participants, Analysis 1.8).

#### Patient-reported symptoms

There were no significant differences in patient-reported symptoms between the two ACTs (two trials, 1807 participants, Analysis 1.9, Analysis 1.10). The trial authors reported symptoms of vomiting, headache, abdominal pain, vertigo, haematuria, upper abdominal pain, and anorexia.

#### Biochemical monitoring and adverse events

Both trials measured biochemical LFTs in all participants at baseline and on days three and seven (Kayentao [@b1] also measured LFTs on day 28), Although the two trials used slightly different grading scales, there were no significant differences between groups in grade 3 or 4 liver toxicity by any of the measures used (two trials, 1807 participants, Analysis 1.11, Analysis 1.12).

#### Haematological monitoring and adverse events

In both trials the mean haemoglobin fell compared to baseline during the first seven days after starting treatment, before recovering by day 28 (two trials, 1807 participants, Analysis 1.12). At day seven the reduction in haemoglobin was greater with artesunate-pyronaridine but this is unlikely to be of clinical significance (MD -0.16, 95% CI -0.28 to -0.05; two trials, 1741 participants, Analysis 1.12).

Kayentao [@b1] also reported the occurrence of anaemia as an adverse event with no differences between groups (one trial, 535 participants, Analysis 1.13).

#### ECG monitoring and adverse events

Both trials conducted ECG monitoring at baseline, days 2, 7, 14 and 28. Tshefu [@b6] reported two participants in each group having abnormal ECG readings and reported these as \"mild\". Kayentao [@b1] reported that there were \"no post-baseline clinically important abnormal ECG results\" (see [Table 7](#tbl7){ref-type="table"}).

#### Subgroup analysis

We have presented a subgroup analysis of PCR-adjusted treatment failure at day 28 by age of participants in Analysis 2.1. This demonstrates the paucity of data for the under-five age group.

Further subgroup analyses by geographical region and country are in Analysis 2.2 and Analysis 2.3. Again, these demonstrate that the data remain severely underpowered to inform national decision-making. Primary outcome data was available for only 194 participants from East Africa, compared to 816 from West Africa, 490 from South-central Africa, and 175 from Asia.

#### Sensitivity analysis

We conducted a sensitivity analysis to explore the influence of different methods for analysing the primary outcome data. For PCR-unadjusted treatment failure, our primary analysis following the WHO guidelines for analysing trials of antimalarials was the least conservative (Analysis 3.1). The per-protocol and intention-to-treat analyses as presented by the trial authors, where missing data were considered treatment failure, were more conservative and the result did not reach statistical significance. For PCR-adjusted treatment failure, there were no substantial differences (Analysis 3.2).

We did not undertake a sensitivity analysis by risk of bias criteria as both of the included trials were at low risk of bias.

### Comparison 2. Artesunate-pyronaridine versus artesunate plus mefloquine

Only one trial, enrolling 1033 participants from Asia and 238 from Africa, compared artesunate-pyronaridine versus artemether-lumefantrine (Rueangweerayut [@b5]). This trial excluded children under five years of age and follow-up was until day 42.

#### Treatment failure

At day 28, the proportion of participants with recurrent parasitaemia was lower in those treated with artesunate-pyronaridine compared to artesunate plus mefloquine (PCR-unadjusted treatment failure: RR 0.35, 95% CI 0.17 to 0.73; one trial, 1200 participants, Analysis 4.1). However, after PCR-adjustment treatment, failure was below 5% with both ACTs with no differences between groups (one trial, 1187 participants, Analysis 4.1).

At day 42, there were no statistically significant differences between artesunate-pyronaridine and artesunate plus mefloquine for PCR-unadjusted or PCR-adjusted treatment failure (one trial, 1146 participants, Analysis 4.2). At this time point, PCR-adjusted treatment failure was 5.8% with artesunate-pyronaridine versus 3.6% with artesunate plus mefloquine.

One person treated with artesunate plus mefloquine experienced early treatment failure and developed cerebral malaria (one trial, 1103 participants, Analysis 4.3).

#### Parasite clearance

The mean parasite clearance time was slightly lower with artesunate-pyronaridine compared to artesunate plus mefloquine (MD 2.60 hours, 95% CI 4.94 to 0.26, one trial, 1259 participants, Analysis 4.4).

#### Fever clearance

Fever clearance time was similar between treatment arms (one trial, 1051 participants, Analysis 4.5).

#### Gametocyte clearance and carriage

Rueangweerayut [@b5] only reported the mean time to gametocyte clearance for the 27 participants (13 on artesunate-pyronaridine versus 14 on artesunate plus mefloquine) who cleared their gametocytes within the first 72 hours. There was no difference between groups (one trial, 27 participants, Analysis 4.6).

#### Serious adverse events

Rueangweerayut [@b5] did not report any deaths. There were nine serious adverse events in total with no significant difference between groups (0.7% with artesunate-pyronaridine versus 0.7% with artesunate plus mefloquine; one trial, 1271 participants, Analysis 4.7).

#### Adverse events leading to withdrawal from treatment

There was no significant difference between groups in the proportion of participants withdrawn from the trial due to adverse events (0.6% with artesunate-pyronaridine versus 0.9% with artesunate plus mefloquine; one trial, 1271 participants, Analysis 4.8).

#### Patient-reported symptoms

Rueangweerayut [@b5] only reported symptoms if they occurred in at least 2% of patients. Dizziness was twice as common in those treated with artesunate plus mefloquine than with artesunate-pyronaridine (RR 0.46, 95% CI 0.28 to 0.78; one trial, 1271 participants, Analysis 4.9). The other reported symptoms were headache, cough, diarrhoea, vomiting, and myalgia.

#### Biochemical monitoring and adverse events

Biochemical tests for liver function monitoring were performed on all participants on days 0, 3, 7, 28, and 42.

Artesunate-pyronaridine was associated with more participants recording elevated ALT and AST levels following treatment. For ALT, grade 2 toxicity (up to five times the upper limit of normal) was significantly higher with artesunate-pyronaridine (21/843 versus 0/417; RR 21.30, 95% CI 1.29 to 350.7; one trial, 1260 participants, Analysis 4.10), and grade 3 or 4 toxicity (= five times the upper limit of normal) approached statistical significance (15/843 versus 0/417; RR 7.41, 95% CI 0.98 to 55.98; one trial, 1260 participants, Analysis 4.11). There were no significant differences for other liver enzymes or bilirubin. No patients developed signs or symptoms of liver disease.

#### Haematological monitoring and adverse events

The mean haemoglobin level fell in both groups during the first seven days after starting treatment (Analysis 4.12) This drop was slightly larger with artesunate-pyronaridine compared to artesunate plus mefloquine (Day 3: MD -0.22 g/dL, 95% CI -0.36 to -0.08; one trial, participants, Analysis 4.12), but by day 28 mean haemoglobin levels were better than baseline in both groups. A similar pattern was observed with platelet counts (Analysis 4.13), and white cell counts (Analysis 4.14). However the differences were small and unlikely to be of clinical significance.

#### ECG monitoring and adverse events

Rueangweerayut [@b5] conducted ECG monitoring on all participants in this trial but the timing and frequency of ECGs was unclear. The trial authors reported abnormal ECGs in under 1% of participants in both groups, and described all abnormalities as mild and transient (one trial, 1271 participants, Analysis 4.15).

#### Subgroup analysis

We did not conduct a subgroup analysis by age of participants as this trial did not include children aged under five years.

We have presented subgroup analyses by geographical region and country in Analysis 5.1 and Analysis 5.2. The majority of PCR-adjusted treatment failures occurred in Thailand and Cambodia, with almost none elsewhere. They also demonstrate the paucity of data from Africa.

Trial authors noted that participants enrolled in Pailin, Cambodia (an area of low-transmission for*P. falciparum*) had significantly longer parasite clearance times than people in the other trial sites; only 63% cleared parasites within 72 hours compared to 98% of participants in the other sites. Recrudescence at this site was reportedly higher with artesunate-pyronaridine than with artesunate plus mefloquine (10.2% versus 0%, P = 0.04; authors\' own figures).

#### Sensitivity analysis

We conducted a sensitivity analysis to explore the influence of different methods for analysing the primary outcome data. For PCR-unadjusted treatment failure, our primary analysis following the WHO guidelines for analysing trials of antimalarials was similar to the per-protocol analysis of the trial authors (Analysis 6.1). In the most conservative estimates the effect size was dramatically reduced and the estimate was no longer statistically significant (Analysis 6.1). For PCR-adjusted treatment failure we did not observe any substantial differences (Analysis 6.2).

We did not perform any further sensitivity analyses as there was only one trial.

### Part 3. Biochemical, haematological and ECG adverse events

In light of concerns about liver toxicity with pyronaridine, we included three additional RCTs of pyronaridine. Two trials compared pyronaridine alone to chloroquine (Ringwald [@b3]; Ringwald [@b4]) and one trial compared artesunate-pyronaridine to chloroquine (Poravuth [@b2]).

#### Biochemical monitoring and adverse events

The six trials reported abnormalities in liver functions in different ways. We assessed the adequacy of monitoring and completeness of results reporting in [Table 5](#tbl5){ref-type="table"}.

Artesunate-pyronaridine was associated with a four-fold increase in the incidence of ALT and AST grade 3 or 4 toxicity (elevations = five times the upper limit of normal) (ALT: RR 4.17, 95% CI 1.38 to 12.62, AST: RR 4.08, 95% CI 1.17 to 14.26; four trials, 3528 participants, Analysis 7.1). Grade 3 or 4 toxicity measured with ALP and bilirubin were not substantially different.

The three main efficacy trials also reported cases with both raised ALT (3 x ULN) and raised bilirubin (2 x ULN) as an indicator for drug induced liver injury (Tshefu [@b6]; Kayentao [@b1]; Rueangweerayut [@b5]). Only five of the 2052 participants in the artesunate-pyronaridine group and one of 1020 participants in the comparator groups had raised ALT and bilirubin. This difference was not statistically significant (three trials, 3072 participants, Analysis 7.2).

Ringwald [@b3] reported that 5/40 participants given pyronaridine had elevated bilirubin levels compared to 0/41 with chloroquine but did not give any further details.

#### Renal function tests

Three trials reported serum creatinine levels as a measure of renal function. At day 7, creatinine values were marginally lower in the pyronaridine-treated group than in those treated with comparator regimens (artemether-lumefantrine, artesunate+mefloquine, chloroquine) (MD -2.76, 95% CI -4.58 to -0.94; three trials, 1808 participants, Analysis 7.3).

#### Haematological monitoring and adverse events

Four trials reported mean haemoglobin on days 0, 3, 7, and 28, and in all four trials the mean haemoglobin fell in both groups between day 0 and day 7 before recovering by day 28 (four trials, 3534 participants, Analysis 7.4). At day 7 the mean haemoglobin was ¼ gram lower in those treated with artesunate-pyronaridine (MD -0.24 g/dL, 95% CI -0.32 to -0.16; four trials, 3394 participants, Analysis 7.4).

#### ECG monitoring and adverse events

Four trials conducted ECG monitoring and ECG adverse effects were rare in all four trials (see [Table 7](#tbl7){ref-type="table"}). Prolonged QT interval was less common with artesunate-pyronaridine than comparators (RR 0.25, 95% CI 0.07 to 0.90; three trials, 2991 participants, Analysis 7.5).

Discussion
==========

Summary of main results
-----------------------

Artesunate-pyronaridine versus artemether-lumefantrine

In two multicentre trials, enrolling mainly older children and adults from west and south-central Africa, both artesunate-pyronaridine and artemether-lumefantrine had fewer than 5% PCR adjusted treatment failures during 42 days of follow-up, with no differences between groups (*low quality evidence*). There were fewer new infections during the first 28 days in those given artesunate-pyronaridine (*moderate quality evidence*), but no difference was detected over the whole 42 day follow-up (*moderate quality evidence*).

Artesunate-pyronaridine versus artesunate plus mefloquine

In one multicentre trial, enrolling mainly older children and adults from South East Asia, both artesunate-pyronaridine and artesunate plus mefloquine had fewer than 5% PCR adjusted treatment failures during 28 days follow-up (*moderate quality evidence*). PCR-adjusted treatment failures had risen to 6% by day 42 in those treated with artesunate-pyronaridine, but this was not substantially different to artesunate plus mefloquine (*low quality evidence*). Again, there were fewer new infections during the first 28 days in those given artesunate-pyronaridine (*moderate quality evidence*), but no differences were detected over the whole 42 days (*low quality evidence*).

Adverse effects

Serious adverse events were rare in these trials with no statistically significant differences between artesunate-pyronaridine and the comparator ACTs. However, biochemical elevation of LFTs occurred four times more frequently with artesunate-pyronaridine than with the other antimalarials (*moderate quality evidence*).

Overall completeness and applicability of evidence
--------------------------------------------------

Artesunate-pyronaridine performed well in all three efficacy trials included in this review, with low levels of PCR-adjusted treatment failure at day 28 in all settings. All three trials were multicentre trials, with trial sites in 11 African countries and six countries in Asia, which broadens the applicability of the findings. However, the actual number of participants recruited from many trial sites was small and the trials were underpowered to evaluate either superiority or equivalence at country level. East Africa is particularly under represented, with only 232 participants from Kenya and Tanzania, and several of the West African countries recruited fewer than 100 participants.

The other major limitation on the applicability of these trials is the age of the participants. The trials predominantly recruited older children and adults. The combination appeared to be effective in these groups but little is known about the main target group; children aged under five years. These trials included only 232 children aged below five years compared to over 7000 in trials of dihydroartemisinin-piperaquine.

Notably, all three efficacy trials excluded people with known pre-existing liver disease, and one trial explicitly excluded those with raised LFTs at baseline. Screening of this kind may not be feasible in many malaria-endemic settings.

Quality of the evidence
-----------------------

We assessed the quality of the evidence in this review using the GRADE approach and presented it in two summary of findings tables for efficacy (Summary of findings for the main comparison; Summary of findings 2).

The evidence that artesunate-pyronaridine is equivalent to established ACTs at preventing PCR-adjusted treatment failures was of moderate quality due to two main concerns:

Indirectness: The trials to date have largely been conducted in older children and adults, with exclusion of young children who bear the greatest burden and risks of malaria infection and illness.Imprecision: The trials were not powered to examine the efficacy of artesunate-pyronaridine in individual regions or countries. This is problematic for national decision-making, and limits the wider generalizability of these results. Larger trials would be required to have full confidence in these results.

We also assessed the quality of evidence on comparative adverse effects and presented these in Appendix 2 and Appendix 3. In general the evidence was of moderate to low quality, and downgraded for similar reasons.

Potential biases in the review process
--------------------------------------

The objectives of the review changed significantly between the published protocol and final review. The basis for the change was to focus on only interventions of relevance to current malaria treatment policies (see Differences between protocol and review). We used standard methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins [@b43]) and complied with the Cochrane Collaboration\'s methodological standards for the conduct of new reviews of interventions (MECIR [@b48]).

We believe that we have identified all pyronaridine trials relevant to inform clinical decisions and policy regarding the use of pyronaridine combinations for the treatment of uncomplicated *P. falciparum* malaria. The three trials were all conducted under the auspices of the public-private partnership, Medicines for Malaria Venture, and Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea.

Agreements and disagreements with other studies or reviews
----------------------------------------------------------

We found one further systematic review of artesunate-pyronaridine published by authors from the Medicines for Malaria Venture (MMV), the co-developers of the artesunate-pyronaridine combination (Duparc [@b38]). The authors include four of the studies included here, plus one study we excluded as it was not randomized (Ramharter [@b24]), and one unpublished study. The authors conclude that \'Pyronaridine-artesunate was well tolerated with no safety concerns with the exception of mostly mild transient rises in transaminases. Efficacy was high and met the requirements for use as first-line therapy\'. While we agree that artesunate-pyronaridine shows promise as a further addition to the ACT combinations, we think it requires further studies in the main target group, children aged less than five years, before countries consider this as a first-line treatment.

Authors\' conclusions
=====================

Implications for practice
-------------------------

Artesunate-pyronaridine performed well in these trials compared to artemether-lumefantrine and artesunate-mefloquine, with PCR-adjusted treatment failure at day 28 below the 5% standard set by the WHO.

Artesunate-pyronaridine is well-tolerated, apart from transient gastrointestinal adverse effects, similar to other antimalarials. However, the potential for liver toxicity in people treated with artesunate-pyronaridine needs further investigation and will necessitate caution in using this treatment combination, particularly in people with pre-existing liver disorders.

Implications for research
-------------------------

Further efficacy and safety studies in African and Asian children are required before this combination could be established as a first or second-line treatment option.

Appendices
==========

Appendix 1. Search methods: search strategies
---------------------------------------------

Search setCIDG SR^a^CENTRALMEDLINE^b^EMBASE^b^LILACS^b^1malariamalariamalariamalariamalaria2pyronaridinepyronaridinepyronaridinepyronaridinepyronaridine31 and 21 and 2NAPHTYRIDINESPYRONARIDINE1 and 24------2 or 32 or 3---5------1 and 41 and 4---6------Limit 5 to humanLimit 5 to human---

^a^Cochrane Infectious Diseases Group Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins [@b42]); upper case: MeSH or EMTREE heading; lower case: free text term.

Appendix 2. Artesunate-pyronaridine versus artemether-lumefantrine adverse events GRADE table
---------------------------------------------------------------------------------------------

Artesunate-pyronaridine compared to artemether-lumefantrine for treating uncomplicated *P. falciparum* malaria**Patient or population:** Patients with uncomplicated *P. falciparum* malaria **Settings:** Malaria endemic areas **Intervention:** Artesunate-pyronaridine (AS-Pyr) **Comparison:** Artemether-lumefantrine (AL6)OutcomesNumber of participants having adverse events (95% CI)Number of participants (trials)Quality of the evidence (GRADE)AL6AS-PyrSerious adverse events (including deaths)3 per 1000**0 more per 1000** (From 2 fewer to 10 more)1787(2 trials)**low** ^1,2,3,4^Adverse events leading to withdrawal17 per 1000**6 more per 1000** (From 6 fewer to 31 more)1787(2 trials)**low** ^1,2,3,4^GastroenterologicalVomiting4 per 100**2 more per 100** (From 1 fewer to 10 more)535(1 trial)**low** ^5,6,7^Diarrhoea------------^8^Abdominal pain5 per 100**0 more per 100** (From 2 fewer to 4 more)1272(1 trial)**low** ^5,9,10^Neuro-psychiatricHeadache3 per 100**0 more per 100** (From 1 fewer to 1 more)1272(1 trial)**low** ^5,9,10^Dizziness------------^8^Cardio-respiratoryCough9 per 100**1 fewer per 100** (From 3 fewer to 2 more)1807(2 trials)**moderate** ^1,2,3,10^ECG abnormality4 per 1000**2 fewer per 1000** (From 4 fewer to 10 more)1272(1 trial)**moderate** ^5,9,10,11^Prolonged QT interval0 per 1000**1 more per 1000** (From 0 fewer to 36 more)1272(1 trial)**moderate** ^5,9,10,11^**Musculoskeletal/** **dermatological**Myalgia------------^8^BiochemicalAlanine aminotransferase\
Grade 3 or 4 toxicity3 per 1000**3 more per 1000** (From 2 fewer to 25 more)1807(2 trials)**low** ^1,2,3,4^Aspartate aminotransferase\
Grade 3 or 4 toxicity1 per 1000**3 more per 1000** (From 0 fewer to 20 more)1807(2 trials)**low** ^1,2,3,4^The **assumed risk** of adverse events in the artemether-lumefantrine group is the average risk across trials. The **corresponding risk** with artesunate-pyronaridine (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.^1^ No serious risk of bias: Both trials were at low risk of bias. ^2^ No serious inconsistency: Statistical heterogeneity was low. ^3^ Downgraded by one for serious indirectness: These two trials included only 232 children aged below five years. ^4^ Downgraded by one for imprecision: These trials do not exclude the possibility of rare but clinically important adverse effects. ^5^ No serious risk of bias: This single trial was at low risk of bias. ^6^ Downgraded by one for serious indirectness: This trial included only 232 children aged less than five years and only 15 less than one year. ^7^ Downgraded by one for serious imprecision: The 95% CI is wide and includes both no difference and clinically important differences. ^8^ This outcome was not reported. ^9^ Downgraded by two for very serious indirectness: This trial excluded children aged less than five years. ^10^ No serious imprecision: The finding is of no difference between treatments and the sample size is adequately powered to detect differences if they existed. ^11^ The second trial only reports that there were \"no clinically important post baseline ECG results\".

Appendix 3. Artesunate-pyronaridine versus artesunate plus mefloquine adverse event GRADE table
-----------------------------------------------------------------------------------------------

Artesunate-pyronaridine compared to artesunate plus mefloquine for treating uncomplicated *P. falciparum* malaria**Patient or population:** Patients with uncomplicated *P. falciparum* malaria **Settings:** Malaria endemic areas **Intervention:** Artesunate-pyronaridine (AS-Pyr) **Comparison:** Artesunate plus mefloquine (AS+MQ)OutcomesNumber of participants having adverse events (95% CI)No of participants (trials)Quality of the evidence (GRADE)AS+MQAS-PyrSerious adverse events (including deaths)7 per 1000**0 more per 1000** (From 5 fewer to 21 more)1271(1 trial)**low** ^1,2,3,4^Adverse events leading to withdrawal9 per 1000**3 fewer per 1000** (From 7 fewer to 7 more)1271(1 trial)**low** ^1,2,3,4^GastroenterologicalVomiting2 per 100**0 more per 100** (From 1 fewer to 2 more)1271(1 trial)**low** ^1,2,5,6^Diarrhoea2 per 1001 fewer per 100\
(From 2 fewer to 0 more)1271(1 trial)**low** ^1,2,5,6^Abdominal pain------------^7^NeuropsychiatricHeadache10 per 100**2 more per 100** (From 2 fewer to 6 more)1271(1 trial)**low** ^1,2,5,6^Dizziness7 per 100**4 fewer per 100** (From 5 fewer to 2 fewer)1271(1 trial)**low** ^1,2,5,6^CardiorespiratoryCough2 per 100**2 more per 100** (From 1 fewer to 4 more)1271(1 trial)**low** ^1,2,5,6^ECG abnormality7 per 1000**0 more per 1000** (From 7 fewer to 21 more)1271(1 trial)**low** ^1,2,3,8^Prolonged QT interval7 per 100**7 fewer per 100** (From 7 fewer to 4 more)1271(1 trial)**moderate** ^1,2,3,6^**Musculoskeletal/** **dermatological**Myalgia4 per 100**2 more per 100** (From 1 fewer to 5 more)1271(1 trial)**low** ^1,2,5,6^BiochemicalAlanine aminotransferase\
Grade 3 or 4 toxicity2 per 1000**16 more per 1000** (From 0 fewer to 110 more)1271(1 trial)**low** ^1,2,3,8^Aspartate aminotransferase\
Grade 3 or 4 toxicity0 per 1000**11 more per 1000** (From 0 more to 161 more)1271(1 trial)**low** ^1,2,3,8^The **assumed risk** of adverse events in the artesunate plus mefloquine group is the risk from the single trial. The **corresponding risk** with artesunate-pyronaridine (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.^1^ No serious risk of bias: This single trial is at low risk of bias. ^2^ No serious inconsistency: Not applicable as only one trial. ^3^ Downgraded by one for serious indirectness: This trial excluded children aged below five years. ^4^ Downgraded by one for imprecision: Trials of this size do not exclude the possibility of rare but clinically important adverse effects. ^5^ Downgraded by two for very serious indirectness: This trial excluded children aged less than five years. ^6^ No serious imprecision: The finding is of no difference between treatments and the sample size is adequately powered to detect differences if they existed. ^7^ This outcome was not reported. ^8^ Downgraded by one for serious imprecision: The 95% CI is wide and includes both no difference and clinically important differences.

Appendix 4. Descriptions of serious adverse events
--------------------------------------------------

Trial IDNumber of participantsComparatorAll serious adverse eventsSerious adverse events judged to be related to the medicationArtesunate-pyronaridineComparatorArtesunate-pyronaridineComparatorKayentao [@b1]535Artemether-lumefantrineComplicated malaria (1)NoneNoneNoneTshefu [@b6]1272Artemether-lumefantrineParotitis (1)\
Typhoid fever (1)\
Urinary tract infection (1)Cerebral malaria (1)Immunosuppresion (1)NoneNoneRueangweerayut [@b5]1271Artesunate-mefloquineAutimmune haemolytic anaemia (1)\
Cholera (1)\
Pneumonia (1)\
Acute pyelonephritis (1)\
Wound infection (1)\
Abortion (1)\
Depression (1)Cerebral malaria (1)\
Seizure (1)\
Grand-mal seizure (1)NoneSeizure (1)\
Grand-mal seizure (1)
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Differences between protocol and review
=======================================

We stated in the protocol that we intended to assess the methods used to generate the allocation sequence and conceal allocation concealment as adequate, inadequate, or unclear according to [@b44], and note who was blinded to the interventions in each trial. However, since the introduction of Review [@b55], we made these assessments using the methods described in Higgins [@b43].

In keeping with the Cochrane Collaboration policy to use \'Summary of findings\' tables, which was introduced after publication of the protocol, we generated them using GRADE profiler (GRADE [@b40]) and interpreted the evidence for each outcome and comparison using the GRADE approach ([@b58]).

We revised the list of outcomes to reflect current WHO standards for assessing outcomes in antimalarial trials.

Although gametocyte carriage was not included as an outcome in the protocol, we included it as a secondary outcome due to its importance in malaria transmission.

In the protocol we stated that we intended to assess the effectiveness of pyronaridine both as a monotherapy and in combination with an artemisinin. However, we revised this to focus only on pyronaridine-artemisinin combinations. In addition, due to concerns regarding pyronaridine\'s effect on the liver, assessment of the effects of the comparisons on liver function now include randomized comparisons in both falciparum and vivax malaria. Accordingly, we updated the background and methods sections considerably to reflect the changing scenario in malaria policies and epidemiology.

PT and HB joined the review team. Rajeev Aravindakshan withdrew from the team due to conflicting demands on his time.

Characteristics of studies
==========================

Characteristics of included studies \[ordered by study ID\]
-----------------------------------------------------------

Kayentao 2012Methods**Trial design:** Randomized, multicentre, open-label, active-controlled, parallel group, non-inferiority trial\
**Period of trial:** November 2007 to November 2008Participants**Number randomized:** 535\
**Age:** Three months to 12 years\
**Gender:** Both\
Inclusion criteria:\
Male or female patients ≤ 12 years of age.Body weight ≥ 5 kg and \< 25 kg with no clinical evidence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviations or less than 70% of the median of the NCHS/WHO normalized reference values).Presence of acute uncomplicated *P. falciparum* mono-infection confirmed by: fever, as defined by axillary temperature ≥ 37.5°C or oral, tympanic, or rectal temperature ≥ 38°C, or documented history of fever in the previous 24 hours and positive microscopy of *P. falciparum* with parasite density between 1,000 and 200,000 asexual parasite count/µL of blood.Written informed consent, in accordance with local practice, provided by parent or guardian. If the parent or guardian is unable to write, witnessed consent is permitted according to local ethical considerations. Where possible, patient assent will be sought.Ability to swallow whole volume of liquid in which medication is suspended.Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the trial period.Ability and willingness to participate based on information given to parent or guardian and access to health facility. The patient is to comply with all scheduled follow-up visits until Day 42.\
Exclusion criteria:\
Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the WHO Criteria.Mixed *Plasmodium* infection.Severe vomiting, defined as = three times in the 24 hours prior to inclusion in the trial or inability to tolerate oral treatment, or severe diarrhoea defined as ≥ three watery stools per day.Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval greater or equal to 450 milliseconds), respiratory (including active tuberculosis), history of jaundice, hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions, or other abnormality (including recent head trauma).Presence of significant anaemia, defined as Hb \< 8 g/dL.Presence of febrile conditions caused by diseases other than malaria.Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, lumefantrine or artesunate or other artemisinins.Patients with known disturbances of electrolytes balance, for example, hypokalaemia or hypomagnesaemia.Use of any other antimalarial agent within two weeks prior to start of the trial as evidenced by reported patient history.Pregnant or breast feeding.Patients taking any drug which is metabolized by the cytochrome enzyme CYP2D6 (flecainide, metoprolol, imipramine, amitriptyline, clomipramine).Received an investigational drug within the past four weeks.Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).Known positive for HIV antibody.LFTs \[ASAT/ALAT levels\] = 2.5 times upper limit of normal range.Known significant renal impairment as indicated by serum creatinine of = 1.4 mg/dL.Previous participation in any clinical trial with pyronaridine artesunate.InterventionsRandomized 2:1 to\
Intervention:\
Fixed-dose oral artesunate-pyronaridine granule formulation (60:20 mg)\* once daily for three days by direct observation (N = 355)\
Control:\
Artemether-lumefantrine crushed tablets (20/120 mg)\*\* twice daily for three days by direct observation (N = 180)\
\*Artesunate-pyronaridine was given once daily: 5 kg to \< 9 kg, one sachet; 9 kg to \<17 kg, two sachets; 17 kg to \< 25 kg, three sachets (dose range 6.7/2.2 to 13.3/4.4 mg/kg/dose mixed in water, milk, or soup)\
\*\*Artemether-lumefantrine was given twice daily crushed and shaken to a suspension in 50 mL water: 5 kg to \< 15 kg, one tablet; 15 kg to \< 25 kg, two tablets (dose range 1.3/8.0 to 4.0/24.0 mg/kg/dose); the second day 0 dose was 8 hrs after the first dose, the first Day 1 dose was 24 hrs after the first Day 0 dose, with all subsequent doses 12 hrs apart.OutcomesPrimary outcomes:\
*Efficacy*\
PCR-corrected adequate clinical and parasitological response rate (ACPR) on Day 28\
*Safety*\
Adverse events (categorized using MedDRA Version 10.1)Laboratory abnormalities (graded using the Division of Microbiology and Infectious Diseases Toxicity Scale (February 2003))\
Secondary outcomes:\
Day 28 crude (non-PCR corrected) ACPRDay 42 PCR-corrected and crude ACPRParasite clearance time (time from first dose until aparasitaemia (two consecutive negative readings taken between 7 and 25 hours apart))Fever clearance time (time from first dose to apyrexia (two consecutive normal readings taken between 7 and 25 hours apart))\
Exploratory efficacy outcomes:\
Proportion of patients with gametocytes\
*Outcomes reported but not used in quantitative synthesis in this review*\
ECG abnormalitiesProportion of patients with parasite clearance or fever clearance on days 1, 2, and 3Gametocyte densityGametocyte clearance time (defined as for parasite clearance time)Notes**Countries of recruitment:** Six countries in Africa (96.3%; Burkina Faso, Democratic Republic of Congo, Gabon, Côte d'Ivoire, Kenya, and Mali) and one in Asia (3.7%; The Philippines).\
**Setting:** Local hospitals and clinics at seven centres in six countries in Africa and one in the Philippines\
**Funding:** Medicines for Malaria Venture, Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea\
**Endemicity:** High\
**Duration of follow-up:** 42 days\
Comment:\
Age range of participants: 45% in Py-AS aged ≤ 5 years, 3.4% \< 1 year; 40% in AL6 aged ≤ 5 years, 1.7% \< 3 yearsSample size estimation: For the primary efficacy outcome the sample size was estimated to have 91% power to reject the null hypothesis (day-28 cure rate ≤90%) using a 1-sided exact binomial test with a nominal significance level of 2.5%; for the main secondary outcome comparing efficacy to artemether-lumefantrine, the sample provided = 99% power to demonstrate non-inferiority of artesunate-pyronaridine versus artemether-lumefantrine with a non-inferiority limit of 10%.Recrudescence was defined with PCR as at least one matching allelic band in the three *P. falciparum* genes*msp1, msp2,* and*glurp* between baseline and post-day 7 samplesTreatment failures were classified as early treatment failure, late clinical failure, and late parasitological failure according to WHO criteria (Bloland [@b30]).Defition of Grade 3 and 4 toxicity: ALT and AST grade 3 toxicity was 10 to 15 times the upper limit of normal, and grade 4 toxicity was = 15 times the upper limit of normal. Total bilirubin grade 3 toxicity was 3.0 to 7.5 times the upper limit of normal.\
**Trials registration:** ClinicalTrials.gov: identifier NCT00541385*Risk of bias*BiasAuthors\' judgementSupport for judgementRandom sequence generation (selection bias)Low riskQuote from report: \"The sponsor provided a computer-generated randomisation schedule. Patients were randomised 2:1 to artesunate-pyronaridine or artemether-lumefantrine\".Allocation concealment (selection bias)Low riskQuotes from report: \" Individually numbered treatment packs of similar appearance were masked on allocation.\"\
Quote from report: \"The study sponsor remained blinded to treatment allocation\".Blinding (performance bias and detection bias) Objective outcomes: parasitological and biochemicalLow riskQuote from report: \"Drugs were given open-label\".\
Quote from report: \"\"Clinical assessments and drug administration were performed by different clinical personnel.\"\
Comment: Unlikely to have introduced detection bias for objective outcomes.Blinding (performance bias and detection bias) Subjective outcomes: adverse eventsLow riskComment: Outcome assessors were blinded to allocation, and were not involved in drug administration.Incomplete outcome data (attrition bias) All outcomesLow riskComment: The participants randomized were accounted for in the trial report and missing data and participants were not differentially distributed in treatment arms, or substantial.Selective reporting (reporting bias)Low riskComment: This trial was prospectively registered and though some changes in the timing of assessments were noticed between the protocol and the trial report, these are not of much importance; all other pre-stated outcomes were adequately reported.Other biasLow riskQuote: \"The sponsors and study site principal investigators developed the protocol, interpreted the data and developed the report. The study sponsors were responsible for data collection and statistical analysis. All authors had access to the primary data, take responsibility for data reporting accuracy and completeness\".\
Comment: Three of the authors are employed by the study sponsors. However, the report states the study sponsors were blind to treatment allocation, and the final report appears to have been approved by all authors. Poravuth 2011Methods**Trial design:** Randomized, multicentre, double-blind, double-dummy, parallel-group, non-inferiority trial\
**Period of trial:** March 2007 to March 2008Participants**Number randomized:** 456\
**Age range:** Seven years to 60 years\
**Gender:** Both\
Inclusion criteria:\
Aged three years to 60 yearsFever or documented fever in the previous 24 hrsMicroscopically confirmed mono-infection with*P. vivax* (parasite density:  ≥ 250 µL with at least 50% asexual parasites/µL blood)Body weight 20 kg to 90 kgWritten informed consent from participants or their guardians, with assent from children able to understand the trialAble to swallow oral medicationWillingness to comply with protocolNegative urine test for pregnancy and agreement to practice contraception (women of child-bearing potential)\
Exclusion criteria:\
Complicated or severe malariaMixed infectionsAnaemia (\< 8 g/dL); severe vomitingClinical severe malnutritionHepatic or renal impairmentPresence or history of clinically important disordersHypersensitivity or allergy to trial drugs or excipientsUse of antimalarials in the previous two weeks by testing; or use of any trial drug for previous four weeksTreatment with any drug metabolised by CYP2D6; pregnant and lactating womenPrevious inclusion in a similar trial of artesunate-pyronaridineInterventionsIntervention:\
Artesunate-pyronaridine tablets (180:60 mg) once daily for three days\* (N = 228)\
Control:\
Chloroquine based on body weight once daily for three days\*\* (N = 228)\
\*For artesunate-pyronaridine, drug dose was based on body weight: 20 kg to 25 kg, 1 tablet; 26 kg to 44 kg, two tablets; 45 kg to 64 kg, three tablets; and 65 kg to 90 kg, four tablets, (giving a artesunate-pyronaridine target dose of between 7.2:2.4 mg/kg and13.8:4.6 mg/kg).\
\*\*The chloroquine dose for adults was 620 mg on Day 0 and 1, and 310 mg on Day 2. The chloroquine target dose for children was 10 mg/kg on Days 0 and 1, and 5 mg/kg on Day 2.OutcomesOutcomes used in this review:\
Adverse events affecting liver functions (Grade 3 and 4 toxicity: aspartate amino transferase, alanine amino transferase, bilirubin)\
*Outcomes reported but not used in this review:*\
Cure rates on days 14, 21, 35, and 42Treatment failureDay 28 cure rateFever clearance timeProportions afebrile and aparasitaemic on days 1, 2, and 3Adverse events other than those affecting liver functionNotes**Countries of recruitment:** Four countries in Asia (Cambodia, India, Indonesia, and Thailand)\
**Setting:** Five local hospitals in four countries in Asia\
**Funding:** Medicines for Malaria Venture, Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea\
**Endemicity:** High\
**Duration of follow-up:** Until day 42\
Comment:\
Age range of participants: 14 (6.1%) in the Py-AS arm and 13 (5.7%) in the chloroquine arm were \< 12 years of ageSample size estimation: Assuming a day-14 cure rate of 95%, and a dropout rate of 10%, the sample size was estimated to provide = 99% power to demonstrate non-inferiority of artesunate-pyronaridine compared to chloroquineG6PD deficiency was detected in 16/228 (7.0%) of patients in each treatment groupPrimaquine was administered to 185/228 (87.3%) patients in the artesunate-pyronaridine group and 181/228 (85.4%) in the chloroquine group starting on Day 28 of the trialDefinitions of Grade 3 and 4 toxicity: Grade 3 toxicity: Hb (65 to 79 g/L); ALT/AST/ALP (5.1 to 10.6 times the upper limit of normal); TBIL (2.6 to 5.6 times the upper limit of normal). Grade 4 toxicity: ALT/AST (=10.6 times the upper limit of normal).\
**Trials registration:** ClinicalTrials.gov identifier: NCT00440999*Risk of bias*BiasAuthors\' judgementSupport for judgementRandom sequence generation (selection bias)Low riskQuote from report: \"A computer-generated randomisation scheme was provided by the sponsor. Subjects were randomised 1:1 within each study site in blocks of six.\"Allocation concealment (selection bias)Low riskQuotes from report: \"Subjects were randomised\...to receive either artesunate-pyronaridine plus matching chloroquine placebo or oral chloroquine plus matching artesunate-pyronaridine placebo\". \"The subject was allocated an individually numbered treatment pack, which contained sufficient tablets for 3 days\' therapy plus an overage bottle containing tablets in case the subject vomited the first dose. All study investigators, laboratory technicians and patients were blind to treatment assignment\". \"Sealed opaque envelopes containing the study medication assignment for each subject were provided to the study site investigator for use in an emergency; no code breaks were required.\"Blinding (performance bias and detection bias) Objective outcomes: parasitological and biochemicalLow riskQuotes from report: \"Study drugs were administered on a double-blind, double-dummy basis. The investigator calculated the appropriate dose and study drug was administered by a different member of staff, designated by the investigator\". \"Active drugs and placebos were packaged similarly.\"Blinding (performance bias and detection bias) Subjective outcomes: adverse eventsLow riskComment: The double-blind, double-dummy design used minimized the risk of performance and detection bias. Pruritis that is common with chloroquine could potentially compromise blinding but was not reported in = 2% of participants.Incomplete outcome data (attrition bias) All outcomesLow riskQuote from report: \" Most patients (83.3%) completed the study. A similar number of patients withdrew prematurely from the study in both groups.\"\
Comment: The results were assessed in per-protocol and intention-to-treat analyses.Selective reporting (reporting bias)Low riskComment: This trial was prospectively registered and reported all pre-stated outcomes adequately.Other biasLow riskQuote from report: \"The sponsors and study site principal investigators developed the protocol, interpreted the data and developed the report. The study sponsors were responsible for data collection and statistical analysis. All authors had access to the primary data, take responsibility for data reporting accuracy and completeness and had responsibility for the final decision to submit for publication.\"\
Comment: Some of the authors are employed by the trial sponsors but all authors had access to data and assumed responsibility for reporting accuracy. Ringwald 1996Methods**Trial design:** Randomized, parallel group, active controlled trial\
**Duration of trial:** Recruitment: April 1994 to May 1995Participants**Number randomized:** 96\
**Age:** 15 to 64 years\
**Gender:** 42 males; 54 females\
Inclusion criteria:Acute falciparum malaria with fever within the past 24 hrs or a temperature above 37.5 °C at the time of consultationOver 5000 asexual parasites/µLNo signs and symptoms of severe and complicated malariaNo recent self-medication\
Exclusion criteria:\
Pregnant womenMixed infectionsInterventionsIntervention\
1. Pyronaridine: 32 mg/kg in divided doses over 3 days\* (N = 47)\
Control\
2. Chloroquine: 25 mg/kg in divided doses over 3 days (N = 49)\
\* Pyronaridine dose: 16 mg/kg on day 1 and 8 mg/kg on days 2 and 3\
\* Chloroquine dose: 10 mg/kg on days 1 and 2 and 5 mg/kg on day 3OutcomesOutcome used in this review:\
Numbers with elevated transaminase enzyme levels at day 7 in those with normal baseline values (extent of elevation not reported)\
*Outcomes reported but used in this review:*\
Fever clearanceParasite clearanceEarly treatment failureParasitaemia on day 14Gametocyte carriage at day 14Adverse events.Haematological (haemoglobin, counts); biochemical mean (liver function values, creatinine, urea).In vitro drug sensitivityNotes**County of recruitment:** Cameroon\
**Setting:** Nlongkak Catholic missionary dispensary in Yaounde; outpatients; all doses of drugs supervised\
**Source of funding:** French Ministere de la Cooperation (Grant 93A43); pyronaridine was supplied by the Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shangai, China\
**Endemicity:** High; 50% to 60% chloroquine resistant\
**Duration of follow-up:** Until day 14 (for all, and in four participants until day 238)\
Comment:\
Proportions with normal transaminase enzyme levels at baseline that were elevated in each arm at day 7 provided in the text of results were used for analysis; the extent of elevation was not reported. The values were normal on day 14 on whom the levels were repeated, but the numbers in whom these were repeated are not reported\
**Trials registration:** Nil*Risk of bias*BiasAuthors\' judgementSupport for judgementRandom sequence generation (selection bias)Low riskQuote from report: \"Patients were randomly assigned in blocks\".\
Comment: Unpublished information provided through correspondence with authors reveal that randomisation was done \"in blocks of 10\".Allocation concealment (selection bias)Low riskComment: Not mentioned in report.\
Quote from correspondence with senior author: \"central randomisation was used\".Blinding (performance bias and detection bias) Objective outcomes: parasitological and biochemicalLow riskComment: Not mentioned in report.\
Quote from correspondence: \"It was blinded but the tablets were different and many patient treated with CQ suffered of pruritus\".\
Comment: Blinding was probably compromised but risk of bias due to this is unlikely to have affected the biochemical outcomes assessing liver functions that were used in this review.Blinding (performance bias and detection bias) Subjective outcomes: adverse eventsLow riskComment: As above.\
Comment: Blinding was probably compromised and risk of bias due to this may have affected the reporting or detection of some subjective adverse events, but only biochemical liver functions were used in this review.Incomplete outcome data (attrition bias) All outcomesLow riskQuote from report: \"After enrolment, six patients treated with chloroquine and five patients treated with pyronaridine were lost to follow-up. Two additional patients from each group were withdrawn because of self-medication with quinine\".\
Quote from correspondence: \"Drop out were mainly lost to follow-up and most often after the patients were cured. We do not think that it was related to intervention.\"\
Comment: Equal numbers dropped out from each intervention arm and hence are unlikely to have differentially influenced liver toxicity outcomes used in this review.Selective reporting (reporting bias)Low riskComment: The trial was not prospectively registered and the trial protocol was not available, but all outcomes stated in methods were reported.Other biasUnclear riskComment: The extent of elevation in liver transaminases and the proportions re-tested at day 14 were not reported. Ringwald 1998Methods**Trial design:** Randomized, parallel group, active controlled trial\
**Duration of trial:** 1996; duration not statedParticipants**Number randomized:** 88\
**Age**: Children in the age range five to 15 years\
**Gender:** Both\
Inclusion criteria:\
Fever at consultation or within previous 24 hrsMonoinfection with *P. falciparum* (parasite density = 5000 asexual parasites/µL blood)Easy access to health servicesInformed consent of parent or guardian\
Exclusion criteria:\
History of self-medication with antimalarials (confirmed by negative urine test)Signs and symptoms of severe or complicated malariaSevere anaemia (haemoglobin \< 5.0 g/dL)Moderate or severe malnutritionInterventionsIntervention:\
1. Pyronaridine: 32 mg/kg (N = 48)\
(16 mg/kg on day 0, in two divided doses; 8 mg/kg on days 1 and 2)\
Control:\
2. Chloroquine: 35 mg/kg (N = 48)\
(10 mg on days 0 and 1; 5 mg on day 2)OutcomesOutcomes used in this review:\
Proportions with normal serum aspartate aminotransferase (AST) enzyme levels at baseline and two-fold or greater elevations at day 7\
*Outcomes reported but not used in this review:*\
Fever clearance (defined as the time from onset of treatment untilRectal temperature remained below 37.5 °C).Parasite clearance (the time required to obtain the first negative thick blood smear with subsequent blood smears remaining negative until day 14).Parasitaemia on day 14Early treatment failureFever clearance timeParasite clearance timeAdverse eventsOthersHaematological (Haemoglobin, counts); biochemical (mean liver functions values, creatinine, urea).In vitro drug sensitivityGametocyte clearanceNotes**Country of recruitment:** Cameroon\
**Setting:** Nlognkak Catholic missionary dispensary in Yaounde; outpatients. All interventions were supervised\
**Source of funding:** Pyronaridine provided by Institute of Parasitic Diseases, Chinese Academy of Preventive Medicine, Shanghai, China\
**Endemicity:** High; 50 to 60% chloroquine resistant\
**Duration of follow-up:** Until day 14\
Comment:\
Proportions on whom transaminase enzyme levels were repeated on day 14 and in those in whom they were normal were not reported\
**Trials registration:** Nil*Risk of bias*BiasAuthors\' judgementSupport for judgementRandom sequence generation (selection bias)Low riskQuote from report: \"Patients were randomly assigned in blocks\".\
Comment: Unpublished information provided by authors suggest that randomisation was done in \"blocks of 10.\"Allocation concealment (selection bias)Low riskComment: Not mentioned in trial report.\
Quote from correspondence with authors: \"central randomisation was used.\"Blinding (performance bias and detection bias) Objective outcomes: parasitological and biochemicalLow riskComment: Not mentioned in report.\
Quote from correspondence: \"It was blinded but the tablets were different and many patient treated with CQ suffered of pruritus\".\
Comment: Blinding was probably compromised but risk of bias due to this may not have affected the reporting of liver enzymes that was the outcome used in this review.Blinding (performance bias and detection bias) Subjective outcomes: adverse eventsLow riskComment: As above.\
Comment: Blinding was probably compromised and risk of bias due to this may have affected the reporting or detection of some subjective adverse events, but not the objective outcome used in this review.Incomplete outcome data (attrition bias) All outcomesLow riskQuote from report: \"Of the 88 patients enrolled in the study, 81 completed the14-day follow-up (dropout rate, 8%). Three patients in the pyronaridine group and four in the chloroquine group were lost to follow-up.\"\
Quote from correspondence: \"Drop out were mainly lost to follow-up and most often after the patients were cured. We do not think that it was related to intervention.\"\
Comment: Equal numbers dropped out from each intervention arm and hence are unlikely to have differentially influenced the outcomes used in this review.Selective reporting (reporting bias)Low riskComment: The trial was not prospectively registered and the trial protocol was not available, but all outcomes stated in methods were reported.Other biasUnclear riskComment: The proportions re-tested for liver transaminases at day 14 and the proportions in whom they were normal were not reported. Rueangweerayut 2012Methods**Trial design:** Randomized, multicentre, parallel-group, double-blind, double-dummy, non-inferiority trial\
**Duration of trial:** January 2007 to October 2008Participants**Numbers randomized:** 1271\
**Age:** Four years to 59 years\
**Gender:** Both\
Inclusion criteria:\
Fever in the last 24 hrsMicroscopically confirmed mono-infection with*P. falciparum* (parasite density: 1000 to 100,000 asexual parasites/µL of blood)Age range 3 years to 60 yearsBody weight 20 kg to 90 kgWritten informed consent from participants or their guardians, with assent from children able to understand the trialAble to swallow oral medicationWillingness to comply with protocolNegative urine test for pregnancy and agreement to practice contraception (women of child-bearing potential)\
Exclusion criteria:\
Complicated or severe malariaMixed infectionsAnaemia (\< 8 g/dL)Severe vomitingSevere malnutritionAny clinically significant illness other than malariaHepatic or renal impairmentKnown hypersensitivity or allergy to trial drugsUse of antimalarials in the previous two weeks; or use of any trial drug for previous four weeksTreatment with any drug metabolised by CYP2D6Pregnant and lactating womenPrevious participation in the trialInterventionsRandomized in a 2:1 ratio to:\
Intervention:\
1. Artesunate-pyronaridine combination (7.2: 2.4 mg/kg respectively) once a day for three days (N = 848)\
Control:\
2. Mefloquine plus artesunate combination (6.2 to 12.5 mg/kg and 2.2 to 5.0 mg/kg respectively) once a day for three days (N = 423)OutcomesPrimary outcome\
PCR-corrected adequate clinical and parasitological response rate (ACPR; absence of parasitaemia, irrespective of axillary temperature, without previous treatment failure) at day 28\
Secondary outcomes\
Adequate clinical and parasitological response rate without correction for reinfection at day 28Parasite clearance time (time from first dose to first negative parasite reading for two consecutive readings 7 to 25 hours apart)Fever clearance time (time from first dose to being afebrile for two consecutive readings 7 to 25 hours apart)Proportion of patients who had cleared parasites at day 1, 2, and 3Proportion of patients without fever at days 1, 2, and 3\
Exploratory efficacy outcomes\
PCR-corrected and uncorrected ACPR rate on day 42Gametocyte carriage\
Safety outcomes\
Incidence of adverse events\
*Outcomes reported but not used in quantitative synthesis*\
Gametocyte clearance timeResults of urinalysis and other clinical laboratory testsResults of electrocardiographyNotes**Countries of recruitment:** Four countries in Asia (Cambodia, India, Thailand, and Vietnam; 81.3%); and three countries in Africa (Bukina Faso, Ivory Coast, Tanzania; 18.7%)\
**Setting:** Local hospitals and health centres\
**Endemicity:** High in most sites\
**Source of funding:** Primary sponsor: Medicines for Malaria Venture; secondary sponsor: Shin Poong Pharmaceuticals\
**Duration of follow-up:** Until day 42\
Comments:\
Age range of participants: 122 (14.4%) in the As-Py arm and 68 (16.1%) in M-AS arm were \< 12 years of ageSample size estimation: Assuming an APCR rate to both treatments of 93%, and a non-inferiority limit of 5%, and a dropout rate of 10%, with two patients receiving pyronaridine--artesunate for every one receiving mefloquine plus artesunate, the sample size was estimated to provide 90% power to demonstrate the non-inferiority of pyronaridine--artesunate with a two-sided 95% CI.Recrudescence differentiated from re-infection by PCR genotyping for *P. falciparum* genes merozoite surface proteins 1 and 2 (*msp1, msp2*), and glutamate-rich protein (*glurp*) with at least one matching allelic band in all markers at baseline and after day 7Grade 3 and 4 toxicity: Adults: Alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase grade 3 toxicity was 5.1 to 10 times and grade 4 toxicity was = 10 times the upper limit of normal. Total bilirubin grade 3 toxicity was 2.6 to 5 times and grade 4 toxicity was = 5 times the upper limit of normal. Children: Alanine aminotransferase, and aspartate aminotransferase, grade 3 toxicity was 10 to 15 times and grade 4 toxicity was = 15 times the upper limit of normal. Total bilirubin grade 3 toxicity was 3.0 to 7.5 times and grade 4 toxicity was = 7.5 times the upper limit of normal.\
**Trials registration:** ClinicalTrials.gov identifier: NCT00403260*Risk of bias*BiasAuthors\' judgementSupport for judgementRandom sequence generation (selection bias)Low riskQuote from report: \"Averion International (now part of Aptiv Solutions) provided the computer generated randomisation schedule.\"\
Quote from trial protocol, \"Patients who meet all entry criteria and present no exclusion criteria will be randomised to receive either pyronaridine artesunate or mefloquine plus artesunate in a 2:1 ratio according to the randomisation scheme provided by the sponsor. Patients will be assigned, in ascending order, a randomisation number according to the order recruited\".Allocation concealment (selection bias)Low riskQuote from trial protocol: \"The patient will be allocated an individual numbered treatment pack which contains sufficient tablets for 3 days therapy plus an overage bottle containing tablets in case the patient vomits the first dose.\"\
Quote from trial protocol, \"Clinical study material will be administered using a third-party single blind design. That is: after determining the eligibility criteria, the investigator shall communicate the patient randomisation number to a qualified study team member (third party) who is not performing clinical assessments. The third party will open the study package and administer the correct amount of tablets as instructed by the investigator to ensure unbiased randomisation.\"Blinding (performance bias and detection bias) Objective outcomes: parasitological and biochemicalLow riskQuote from report: \"Drugs were administered by an investigator who was aware of group assignments; clinical and parasitologic assessments were performed by investigators who were aware of group assignments\".\
Comment: The use of blinded outcome assessors minimised the risk of detection bias for objective outcomes.Blinding (performance bias and detection bias) Subjective outcomes: adverse eventsLow riskQuote from report: \"Clinical and parasitological assessments were performed by investigators who were not aware of group assignments.\"\
Comment: Most of the outcomes used in this review were objective outcomes, so participant\'s knowledge of treatment allocation is not likely to introduce bias.Incomplete outcome data (attrition bias) All outcomesLow riskComment: Data regarding all participants recruited provided in results for all outcomes.Selective reporting (reporting bias)Low riskComment: The trial was prospectively registered and the protocol was also available; all pre-stated outcomes were reported adequately.Other biasLow riskQuote from report: \"The study was designed by the authors and the study sponsors, the Medicines for Malaria Venture and Shin Poong Pharmaceutical Company. All the authors vouch for the completeness and accuracy of the data and the analysis and for the fidelity of the study to the protocol\".\
Quote from report: \"No potential conflict of interest relevant to this article was reported\".\
Comment: Some of the authors are employed by the trial sponsors but all authors had access to data and assumed responsibility for reporting accuracy. Tshefu 2010Methods**Trial design:** Randomized, multi centre, parallel-group, double-blind, double-dummy, non-inferiority trial\
**Period of trial:** January 2007 to April 2008Participants**Number randomized:** 1272\
**Age range:** Five to 60 years \
**Gender:** Both\
Inclusion criteria:\
Age between 3 to 60 yearsFever in the last 24 hrsMicroscopically confirmed mono-infection with*P. falciparum* (parasite density: 1000 to 100,000 asexual parasites/µL of blood)Body weight 20 to 90 kgWritten informed consent from participants or their guardians, with assent from children able to understand the trialAble to swallow oral medicationWillingness to comply with protocolNegative urine test for pregnancy and agreement to practice contraception (women of child-bearing potential)\
Exclusion criteria:\
Complicated or severe malariaMixed infectionsAnaemiaSevere vomitingMalnutritionHepatitisHypersensitivity or allergy to trial drugsUse of antimalarials in the previous two weeks by testing; or use of any trial drug for previous four weeksTreatment with any drug metabolised by CYP2D6Pregnant and lactating womenPrevious inclusion in a similar trial of artesunate-pyronaridineInterventionsRandomized in a 2:1 ratio to:\
Intervention:\
1. artesunate-pyronaridine combination (180 mg and 60 mg)\* once a day for three days according to bodyweight (N = 849)\
Control:\
2. Artemether-lumefantrine combination (20 mg and 120 mg)\*\* twice a day for three days according to bodyweight (N = 423)\
\*Average dose of pyronaridine: 9 mg/Kg body weight (range 13.8 to 7.2 mg/ Kg); artesunate doses ranged from 2.3 to 4.7 mg/kg body weight\
\*\*Mean artemether dose: 1.7 mg/kg (range 0.9 to 2.4 mg/kg); lumefantrine doses ranged from 5 to 14.4 mg/kgOutcomesPrimary outcome\
PCR-corrected adequate clinical and parasitological response rate (APCR; absence of parasitaemia, irrespective of axillary temperature, without previous treatment failure) at day 28\
(Sensitivity analysis done with crude APCR (non-PCR-corrected) at day 28)\
Secondary outcomes\
Parasite clearance time (time from first dose to first negative parasite reading for two consecutive readings 7 to 25 hours apart)Fever clearance time (time from first dose to being afebrile for two consecutive readings 7 to 25 hours apart)\
Exploratory efficacy outcomes\
PCR-corrected and uncorrected APCR rate on day 42Number of gametocytes per micro-litre at days 0, 3, 7, 14, 21, and 42\
Safety outcomes\
Serious adverse events (death, life threatening, requiring hospital admission or extended hospital stay, resulting in a congenital abnormality or birth defect, persistent disability or incapacity, or other serious adverse event)Other adverse events (during treatment and at follow-up on days 7, 14, 21, 28, 35, and 42)Laboratory abnormalities (days 3, 7; if indicated days 28, 42)\
*Outcome reported but not used in quantitative synthesis in this review*\
Proportion of patients who had cleared parasites at day 1, 2, and 3Proportion of patients without fever at days 1, 2, and 3Electrocardiograph abnormalities (days 2, 7, 14, and 28)Notes**Countries of recruitment:** Seven countries in Africa (Democratic Republic of Congo, The Gambia, Ghana; Kenya; Mali; Mozambique; and Senegal) recruited over 1000 participants; remainder were from three sites in two countries in southeast Asia (two in Indonesia; one in the Phillipines)\
**Setting:** Local hospitals and clinics\
**Source of funding:** Primary sponsor: Medicines for Malaria Venture; secondary sponsor: Shin Poong Pharmaceuticals\
**Endemicity:** All are high endemic areas\
Comments:\
Age rage of participants: 378 (45%) in the Py-As arm and 182 (43%) in the AL6 arm were aged five to 12 yearsFood was not required for artemether-lumefantrine (to retain blinding)Non-inferiority was shown if the lower limit of the two-sided 95% CI for the difference between groups was greater than -5%Recrudescence was differentiated from re-infection by PCR genotyping for *P. falciparum* genes merozoite surface proteins 1 and 2 (*msp1, msp2*), and glutamate-rich protein (*glurp*) with at least one matching allelic band in all markers at baseline and after day 7Grade 3 or 4 toxicity: For alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase, grade 3 toxicity was 5·1 to 10 times the upper limit of normal and grade 4 toxicity was more than ten times the upper limit of normal. For total bilirubin, grade 3 toxicity was 2·6 to 5 times the upper limit of normal and grade 4 toxicity was more than five times the upper limit of normal.\
**Trials registration:** ClinicalTrials.gov identifier: NCT00422084*Risk of bias*BiasAuthors\' judgementSupport for judgementRandom sequence generation (selection bias)Low riskQuote from report: \"A computer generated randomisation schedule was provided by Averion AG (Allschwil, Switzerland). Patients were assigned a randomisation code by the investigator in ascending order and allocated to treatment in blocks of nine by study centre.\"Allocation concealment (selection bias)Low riskQuote from report: \"Patients were allocated an individual numbered treatment pack containing sufficient tablets for 3 days therapy plus an overage bottle containing an extra dose in case the patient vomited the first dose. Study packages were allocated on the basis of patient randomisation number. A qualified study team member (third party) who was not undertaking clinical assessments opened the study package and administered the correct amount of tablets, based on patient weight at screening, as instructed by the investigator.\"Blinding (performance bias and detection bias) Objective outcomes: parasitological and biochemicalLow riskQuote from report: \"All clinical and laboratory staff and patients were masked to treatment allocation.\"\
Quote from report: \"Study drugs and placebos were presented in identical packaging. Artemether-lumefantrine placebo was dosed twice daily to maintain blinding. Placebos were of similar shape and colour to their respective active drug.\"\
Quote from report: \"Sealed opaque envelopes of treatment allocation were provided for use in an emergency, although no code breaks were necessary.\"\
Quote from report: \"Food was not required for artemether-lumefantrine dosing to retain blinding.\"Blinding (performance bias and detection bias) Subjective outcomes: adverse eventsLow riskComment: See quotes above.Incomplete outcome data (attrition bias) All outcomesLow riskComment: Data regarding all participants recruited provided in results for all outcomes.Selective reporting (reporting bias)Low riskQuote from report: \"There were no changes to study outcomes after trial commencement.\"\
Comment: The trial was prospectively registered. No changes were noted in the details provided in the registration document and the study report for outcomes.\
Comment: Day 42 efficacy outcomes and gametocyte counts were not listed in trial registration document and are listed in the report as exploratory.Other biasUnclear riskComment: Sponsors designed the trial, were responsible for data collection and analysis, and developed the report; all authors had access to trial data.\
Comment: Participants on artemether-lumefantrine were not expected to take medication after food; unclear if this reduced bioavailability of lumefantrine, particularly for day 42 outcomes and reinfection rate when lumefantrine levels may have been low.

Characteristics of excluded studies \[ordered by study ID\]
-----------------------------------------------------------

StudyReason for exclusionCai 1999Not a RCT: Case series.Chang 1997Not a RCT: Case series.Che 1987Quasi-RCT. Odd and even numbers used for allocation.Che 1990Not a RCT: Controlled clinical trial.Chen 1989Not a RCT: Field trial.Fleckenstein 2007Not a RCT: Controlled clinical trial evaluating drug pharmacokinetics.Huang 1988  Quasi-RCT. Randomized according to order of admission.Huang 1989Quasi-RCT. Odd and even numbers used for allocation.\
Compared plain and enteric coated tablets of pyronaridineHuang 1993RCT: Conducted in people with complicated falciparum malaria (malignant malaria).Huang 1996RCT: Compared single dose versus two days of the same drug combination.Liu 2002RCT: Compared pyronaridine + dihydroartemisinin versus dihydroartemisinin alone and with pyronaridine alone. No ACT comparator; no data on liver functions provided in report to include for \"Adverse event affecting liver functions\".Looareesuwan 1996  Not a RCT: Clinical trial of two doses of pyronaridine monotherapy with group given second dose recruited after results of first dose were analysed.Looareesuwan 2007RCT: Phase II dose ranging trial.NCT01156389RCT: ongoing trial evaluating drug interactions in healthy volunteers.No authors listed 1985Not a RCT: field trial.Pang 1989Not a RCT: controlled clinical trial comparing tablets versus intramuscular injections of pyronaridine/sulfadoxine/pyrimethamine.Piola 2008Not a RCT: phase II dose ranging study.Ramharter 2008Quasi-RCT. Sequential allocation; Phase II dose ranging trial.Shao 1991Not a RCT: case series.Tan 2008Not a RCT: Pharmacokinetic study in healthy volunteers.Wattanavijitkul 2008Not a RCT: Pharmacokinetic study in healthy volunteers.
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Summary of Findings for the Main Comparison\[Explanation\]
==========================================================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------- -------------------------------- ------------------------------------
  **Artesunate-pyronaridine compared to artemether-lumefantrine for treating people with uncomplicated falciparum malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **Patient or population:** Adults and children with uncomplicated falciparum malaria **Settings:** Malaria endemic areas in Africa and Asia **Intervention:** Artesunate-pyronaridine **Comparison:** Artemether-lumefantrine                                                                                                                                                                                                                                                                                                                                                                                                                        

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Illustrative comparative risks\* (95% CI)**   **Relative effect(95% CI)**   **No of participants(trials)**   **Quality of the evidence(GRADE)**

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Corresponding risk**                                                                                         

  **Artemether-lumefantrine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **Artesunate-pyronaridine**                                                                                    

  **Treatment failure (day 28)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **PCR-unadjusted**                              **RR 0.60** (0.40 to 0.90)    1720(2 trials)                   ⊕⊕⊕○ **moderate** ^1,2,3,4^

  **7 per 100**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **4 per 100** (3 to 6)                                                                                         

  **PCR-adjusted**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **RR 1.69** (0.56 to 5.10)                      1650(2 trials)                ⊕⊕⊕○ **moderate** ^1,2,3,5^      

  **1 per 100**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **1 per 100** (0 to 4)                                                                                         

  **Treatment failure (Day 42)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **PCR-unadjusted**                              **RR 0.85** (0.53 to 1.36)    1691\                            ⊕⊕⊕○ **moderate** ^1,2,3,5^
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      (2 trials)                       

  **17 per 100**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **15 per 100** (9 to 23)                                                                                       

  **PCR-adjusted**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **RR 1.53** (0.73 to 3.19)                      1472(2 trials)                ⊕⊕○○l**ow** ^1,6,3,5^            

  **2 per 100**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **3 per 100** (1 to 6)                                                                                         

  The **assumed risk** is the mean risk across the trials in those treated with artemether-lumefantrine. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                           

  GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------- -------------------------------- ------------------------------------

^1^ No serious risk of bias: Both trials were well conducted and at low risk of bias.

^2^ No serious inconsistency: The trend was towards benefit with artesunate-pyronaridine in both trials but only reached statistical significance in one.

^3^ Downgraded by one for serious indirectness: The two trials were conducted in children aged between three months and 12 years and had trial sites in Africa and Asia. However across both trials only 152 children aged \< five years received artesunate-pyronaridine, and only 115 children in total were randomized to artesunate-pyronaridine in Asia. Further adequately powered studies in children in Africa and adults and children in Asia would be needed to fully generalize this result.

^4^ No serious imprecision: The result is statistically significant and the meta-analysis is adequately powered. However, it should be noted that these multicentred trials are underpowered to show equivalence at the country level. We did not downgrade.

^5^ No serious imprecision: The finding is of no substantial difference between the two ACTs. However, it should it should be noted that these multicentred trials are underpowered to show equivalence at the country level. We did not downgrade.

^6^ Downgraded by one for serious inconsistency: Although statistical heterogeneity was low, PCR-adjusted treatment failure was above 5% in on the one trial recruiting children aged \< five years.

^7^ For adverse events see the additional Summary of Findings table in Appendix 2.

Artesunate-pyronaridine compared to artesunate plus mefloquine for treating uncomplicated *P. falciparum* malaria
=================================================================================================================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------- -------------------------------- ------------------------------------
  **Artesunate-pyronaridine compared to artesunate plus mefloquine for treating people with uncomplicated *P. falciparum* malaria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  **Patient or population:** People with uncomplicated*P. falciparum* malaria **Settings:** Malaria endemic areas in Africa and Asia **Intervention:** Artesunate-pyronaridine **Comparison:** Artesunate plus mefloquine                                                                                                                                                                                                                                                                                                                                                                                                                              
  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Illustrative comparative risks\* (95% CI)**   **Relative effect(95% CI)**   **No of participants(trials)**   **Quality of the evidence(GRADE)**
  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Corresponding risk**                                                                                         
  **Artesunate-mefloquine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             **Artesunate-pyronaridine**                                                                                    
  **Treatment failure (Day 28)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **PCR-unadjusted**                              **RR 0.35** (0.17 to 0.73)    1200(1 trial)                    ⊕⊕⊕○ **moderate** ^1,2,3,4^
  **4 per 100**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **2 per 100** (1 to 2)                                                                                         
  **PCR-adjusted**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **RR 0.38** (0.14 to 1.02)                      1187(1 trial)                 ⊕⊕⊕○ **moderate** ^1,2,3,5^      
  **2 per 100**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **1 per 100** (0 to 2)                                                                                         
  **Treatment failure (Day 42)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **PCR-unadjusted**                              **RR 0.86** (0.57 to 1.31)    1146(1 trial)                    ⊕⊕⊕○ **moderate** ^1,2,3,5^
  **8 per 100**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         **7 per 100** (5 to 11)                                                                                        
  **PCR-adjusted**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **RR 1.64** (0.89 to 3.00)                      1116(1 trial)                 ⊕⊕○○l**ow** ^1,2,3,5,6^          
  **4 per 1000**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        **6 per 100** (3 to 11)                                                                                        
  The **assumed risk** is the risk in the group treated with artesunate plus mefloquine in the single trial. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                       
  GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------- -------------------------------- ------------------------------------

^1^ No serious risk of bias: This trial was well conducted with low risk of bias.

^2^ No serious inconsistency: Not applicable as only one trial.

^3^ Downgraded by one for serious indirectness: Of the 1271 children and adults aged greater than five years enrolled in this trial, 81.3% (1033) were enrolled and treated in trial sites in Asia (Cambodia, India, Thailand, Vietnam), and only 18.7% (237) in Africa (Bukina Faso, Ivory Coast, and Tanzania). Further studies in African children are necessary to fully generalize this result.

^4^ No serious imprecision: The result is statistically significant and the meta-analysis is adequately powered. However, it should be noted that this multicentred trial is underpowered to show equivalence at the country level. Not downgraded.

^5^ No serious imprecision: The result is of no clinically important differences between ACTs. However, it should be noted that this multicentred trial is underpowered to show equivalence at the country level. Not downgraded.

^6^ PCR-adjusted treatment failure was just above 5% with artesunate-pyronaridine in this trial.

^7^ For adverse events see the additional Summary of Findings table in Appendix 3.

Liver toxicity of pyronaridine compared to other antimalarials
==============================================================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------- ------------------------------------ ------------------------------------ -----------------------------
  **Liver toxicity of pyronaridine compared to other antimalarials**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  **Patient or population:** People with uncomplicated falciparum malaria **Settings:** High and low-transmission settings for *P. falciparum* and *P. vivax* malaria **Intervention:** Pyronaridine alone or with an artemisinin-derivative **Comparison:** Another antimalarial                                                                                                                                                                                                                                                                                                                                                                                                               

  **Outcomes**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **Illustrative comparative risks\* (95% CI)**   **Relative effect(95% CI)**   **Number of participants(trials)**   **Quality of the evidence(GRADE)**   

  **Assumed risk**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **Corresponding risk**                                                                                                                                  

  **Comparator antimalarial**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           **Pyronaridine alone or with artesunate**                                                                                                               

  **Elevated alanine aminotransaminase levels** Grade 3,4 toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                      **2 per 1000**                                  **10 per 1000** (3 to 30)     **RR 4.17** (1.38 to 12.61)          3523(4 trials)                       ⊕⊕⊕○ **moderate** ^1,2,3,4^

  **Elevated aspartate aminotransferase levels**\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **2 per 1000**                                  **8 per 1000** (2 to 29)      **RR 4.08** (1.17 to 14.26)          3528(4 trials)                       ⊕⊕⊕○ **moderate** ^1,2,3,4^
  Grade 3, 4 toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  **Elevated alkaline phosphatase levels** Grade 3, 4 toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                          **2 per 1000**                                  **1 per 1000** (0 to 5)       **RR 0.62** (0.15 to 2.51)           2606(3 trials)                       ⊕⊕⊕○ **moderate** ^1,2,3,5^

  **Elevated bilirubin** Grade 3, 4 toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            **3 per 1000**                                  **6 per 1000** (2 to 19)      **RR 1.92** (0.59 to 6.24)           3067(3 trials)                       ⊕⊕○○l**ow** ^1,2,3,6^

  \*The basis for the **assumed risk** (for example, the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio.                                                                                                                                                                                                                                                                                                                                                 

  GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.                                                                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------- ------------------------------------ ------------------------------------ -----------------------------

^1^ No serious risk of bias: Trials were well conducted, although the data analysis was not clearly independent of the drug manufacturer in three trials.

^2^ No serious inconsistency: Statistical heterogeneity was low.

^3^ Downgraded by one for serious indirectness: Only 232 children aged less than five years were included in these trials.

^4^ No serious imprecision: The 95% CI is wide, and there are few events. Larger trials would be necessary to have full confidence in this result but not downgraded.

^5^ No serious imprecision: The 95% CI is narrow and probably excludes clinically important differences.

^6^ Downgraded by one for serious imprecision: The 95% CI is wide and includes no difference and clinically important effects.

Data And Analysis
=================

Comparison 1. Artesunate-pyronaridine versus artemether-lumefantrine
--------------------------------------------------------------------

  Outcome or subgroup title                               No. of studies   No. of participants   Statistical method                    Effect size
  ------------------------------------------------------- ---------------- --------------------- ------------------------------------- -------------------------
  1 Total failure (Day 28)                                2                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  1.1 PCR-unadjusted                                      2                1720                  Risk Ratio (M-H, Fixed, 95% CI)       0.60 \[0.40, 0.90\]
  1.2 PCR-adjusted                                        2                1650                  Risk Ratio (M-H, Fixed, 95% CI)       1.69 \[0.56, 5.10\]
  2 Total failure (Day 42)                                2                                      Risk Ratio (M-H, Random, 95% CI)      Subtotals only
  2.1 PCR-unadjusted                                      2                1691                  Risk Ratio (M-H, Random, 95% CI)      0.85 \[0.53, 1.36\]
  2.2 PCR-adjusted                                        2                1472                  Risk Ratio (M-H, Random, 95% CI)      1.53 \[0.73, 3.19\]
  3 Early treatment failure                               2                1676                  Risk Ratio (M-H, Fixed, 95% CI)       0.74 \[0.12, 4.42\]
  4 Parasite clearance time (hours)                       1                1170                  Mean Difference (IV, Fixed, 95% CI)   -3.20 \[-4.38, -2.02\]
  5 Fever clearance time (hours)                          1                1170                  Mean Difference (IV, Fixed, 95% CI)   -1.20 \[-2.38, -0.02\]
  6 Gametocyte clearance time                             1                1170                  Mean Difference (IV, Fixed, 95% CI)   -10.5 \[-12.40, -8.60\]
  7 Serious adverse events                                2                1787                  Risk Ratio (M-H, Fixed, 95% CI)       0.92 \[0.20, 4.28\]
  8 Adverse events leading to withdrawal from treatment   2                1787                  Risk Ratio (M-H, Fixed, 95% CI)       1.37 \[0.67, 2.82\]
  9 Patient reported symptoms                             2                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  9.1 Headache                                            1                1272                  Risk Ratio (M-H, Fixed, 95% CI)       0.86 \[0.60, 1.24\]
  9.2 Cough                                               2                1807                  Risk Ratio (M-H, Fixed, 95% CI)       0.85 \[0.62, 1.17\]
  9.3 Abdominal pain                                      1                1272                  Risk Ratio (M-H, Fixed, 95% CI)       1.08 \[0.67, 1.75\]
  9.4 Vomiting                                            1                535                   Risk Ratio (M-H, Fixed, 95% CI)       1.58 \[0.73, 3.44\]
  9.5 Pyrexia                                             1                535                   Risk Ratio (M-H, Fixed, 95% CI)       1.46 \[0.67, 3.19\]
  9.6 Influenza- like illness                             1                535                   Risk Ratio (M-H, Fixed, 95% CI)       1.20 \[0.54, 2.70\]
  10 Patient reported symptoms judged as drug-related     2                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  10.1 Vomiting                                           2                1807                  Risk Ratio (M-H, Fixed, 95% CI)       1.25 \[0.68, 2.31\]
  10.2 Headache                                           1                1272                  Risk Ratio (M-H, Fixed, 95% CI)       1.03 \[0.57, 1.85\]
  10.3 Abdominal pain                                     1                1272                  Risk Ratio (M-H, Fixed, 95% CI)       1.25 \[0.60, 2.57\]
  10.4 Vertigo                                            1                1272                  Risk Ratio (M-H, Fixed, 95% CI)       1.49 \[0.48, 4.61\]
  10.5 Haematuria                                         1                1272                  Risk Ratio (M-H, Fixed, 95% CI)       2.49 \[0.55, 11.32\]
  10.6 Upper abdominal pain                               1                1272                  Risk Ratio (M-H, Fixed, 95% CI)       1.12 \[0.35, 3.62\]
  10.7 Anorexia                                           1                1272                  Risk Ratio (M-H, Fixed, 95% CI)       0.33 \[0.09, 1.17\]
  11 Abnormal LFTs; grade 3 and 4 toxicity                2                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  11.1 Alanine aminotransferase (ALT)                     2                1807                  Risk Ratio (M-H, Fixed, 95% CI)       2.00 \[0.43, 9.42\]
  11.2 Asparatate aminotransferase (AST)                  2                1807                  Risk Ratio (M-H, Fixed, 95% CI)       3.85 \[0.70, 21.09\]
  11.3 Alkaline phosphatase (ALP)                         1                1272                  Risk Ratio (M-H, Fixed, 95% CI)       0.10 \[0.00, 2.07\]
  11.4 Bilirubin                                          2                1807                  Risk Ratio (M-H, Fixed, 95% CI)       1.30 \[0.30, 5.62\]
  12 Change in haemoglobin                                2                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  12.1 Haemoglobin at baseline                            2                1807                  Mean Difference (IV, Fixed, 95% CI)   -0.03 \[-0.19, 0.13\]
  12.2 Haemoglobin day 3                                  2                1755                  Mean Difference (IV, Fixed, 95% CI)   -0.01 \[-0.13, 0.11\]
  12.3 Haemoglobin day 7                                  2                1741                  Mean Difference (IV, Fixed, 95% CI)   -0.16 \[-0.28, -0.05\]
  12.4 Haemoglobin day 28                                 2                1702                  Mean Difference (IV, Fixed, 95% CI)   0.04 \[-0.09, 0.18\]
  13 Anaemia as an adverse event                          1                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  13.1 Anaemia (AE of any cause)                          1                535                   Risk Ratio (M-H, Fixed, 95% CI)       1.23 \[0.68, 2.23\]
  13.2 Anaemia (drug- related AE)                         1                535                   Risk Ratio (M-H, Fixed, 95% CI)       0.69 \[0.32, 1.47\]

Comparison 2. Artesunate-pyronaridine versus artemether-lumefantrine; subgroup analysis
---------------------------------------------------------------------------------------

  Outcome or subgroup title                                      No. of studies   No. of participants   Statistical method                Effect size
  -------------------------------------------------------------- ---------------- --------------------- --------------------------------- ----------------------
  1 Total failure PCR-adjusted (Day 28); subgrouped by age       2                                      Risk Ratio (M-H, Fixed, 95% CI)   Subtotals only
  1.1 Age = 5 years                                              2                1469                  Risk Ratio (M-H, Fixed, 95% CI)   1.01 \[0.25, 4.03\]
  1.2 Age \< 5 years                                             1                216                   Risk Ratio (M-H, Fixed, 95% CI)   3.37 \[0.43, 26.38\]
  2 Total failure PCR-adjusted (Day 28); subgrouped by region    2                1675                  Risk Ratio (M-H, Fixed, 95% CI)   1.10 \[0.44, 2.76\]
  2.1 West Africa                                                2                816                   Risk Ratio (M-H, Fixed, 95% CI)   1.42 \[0.29, 6.92\]
  2.2 East Africa                                                2                194                   Risk Ratio (M-H, Fixed, 95% CI)   2.64 \[0.13, 53.14\]
  2.3 South-central Africa                                       2                490                   Risk Ratio (M-H, Fixed, 95% CI)   0.67 \[0.15, 2.92\]
  2.4 Asia                                                       2                175                   Risk Ratio (M-H, Fixed, 95% CI)   1.02 \[0.09, 10.99\]
  3 Total failure PCR-adjusted (Day 28); subgrouped by country   2                1675                  Risk Ratio (M-H, Fixed, 95% CI)   0.94 \[0.41, 2.18\]
  3.1 Burkina Faso                                               1                25                    Risk Ratio (M-H, Fixed, 95% CI)   1.05 \[0.05, 22.91\]
  3.2 DR Congo                                                   2                369                   Risk Ratio (M-H, Fixed, 95% CI)   0.5 \[0.10, 2.43\]
  3.3 Gabon                                                      1                78                    Risk Ratio (M-H, Fixed, 95% CI)   0.17 \[0.01, 4.03\]
  3.4 Ivory Coast                                                1                100                   Risk Ratio (M-H, Fixed, 95% CI)   2.25 \[0.27, 18.43\]
  3.5 Kenya                                                      2                194                   Risk Ratio (M-H, Fixed, 95% CI)   2.64 \[0.13, 53.14\]
  3.6 Mali                                                       2                318                   Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.7 The Gambia                                                 1                90                    Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.8 Ghana                                                      1                7                     Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.9 Mozambique                                                 1                121                   Risk Ratio (M-H, Fixed, 95% CI)   1.5 \[0.06, 36.02\]
  3.10 Senegal                                                   1                198                   Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.11 Phillipines                                               2                107                   Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  3.12 Indonesia                                                 1                68                    Risk Ratio (M-H, Fixed, 95% CI)   0.89 \[0.09, 9.32\]

Comparison 3. Artesunate-pyronaridine versus artemether-lumefantrine; sensitivity analysis
------------------------------------------------------------------------------------------

  Outcome or subgroup title                                       No. of studies   No. of participants   Statistical method                Effect size
  --------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  1 Total failure PCR-unadjusted (Day 28); Sensitivity analysis   2                                      Risk Ratio (M-H, Fixed, 95% CI)   Subtotals only
  1.1 Primary analysis (Cochrane review)                          2                1720                  Risk Ratio (M-H, Fixed, 95% CI)   0.60 \[0.40, 0.90\]
  1.2 Missing data included as failures                           2                1807                  Risk Ratio (M-H, Fixed, 95% CI)   0.77 \[0.58, 1.03\]
  1.3 Missing data included as successes                          2                1807                  Risk Ratio (M-H, Fixed, 95% CI)   0.61 \[0.41, 0.90\]
  1.4 Intention to treat analysis (of trial authors)              2                1807                  Risk Ratio (M-H, Fixed, 95% CI)   0.77 \[0.58, 1.03\]
  1.5 Per-protocol analysis (of trial authors)                    2                1683                  Risk Ratio (M-H, Fixed, 95% CI)   0.66 \[0.43, 1.01\]
  2 Total failure PCR-adjusted (Day 28); Sensitivity analysis     2                                      Risk Ratio (M-H, Fixed, 95% CI)   Subtotals only
  2.1 Primary analysis (Cochrane review)                          2                1650                  Risk Ratio (M-H, Fixed, 95% CI)   1.69 \[0.56, 5.10\]
  2.2 Missing or indeterminate PCR results included as failures   2                1651                  Risk Ratio (M-H, Fixed, 95% CI)   1.35 \[0.49, 3.73\]
  2.3 New infections included as successes                        2                1720                  Risk Ratio (M-H, Fixed, 95% CI)   1.41 \[0.51, 3.88\]
  2.4 Missing data included as failures                           2                1807                  Risk Ratio (M-H, Fixed, 95% CI)   1.06 \[0.71, 1.57\]
  2.5 Missing data included as successes                          2                1807                  Risk Ratio (M-H, Fixed, 95% CI)   1.41 \[0.51, 3.89\]
  2.6 Intention to treat analysis (by trial authors)              2                1807                  Risk Ratio (M-H, Fixed, 95% CI)   0.87 \[0.60, 1.24\]
  2.7 Per-protocol analysis (by trial authors)                    2                1676                  Risk Ratio (M-H, Fixed, 95% CI)   1.38 \[0.50, 3.81\]

Comparison 4. Artesunate-pyronaridine versus artesunate-mefloquine
------------------------------------------------------------------

  Outcome or subgroup title                               No. of studies   No. of participants   Statistical method                    Effect size
  ------------------------------------------------------- ---------------- --------------------- ------------------------------------- -------------------------
  1 Total failure (Day 28)                                1                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  1.1 PCR-unadjusted                                      1                1200                  Risk Ratio (M-H, Fixed, 95% CI)       0.35 \[0.17, 0.73\]
  1.2 PCR adjusted                                        1                1187                  Risk Ratio (M-H, Fixed, 95% CI)       0.38 \[0.14, 1.02\]
  2 Total failure (Day 42)                                1                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  2.1 PCR-unadjusted                                      1                1146                  Risk Ratio (M-H, Fixed, 95% CI)       0.86 \[0.57, 1.31\]
  2.2 PCR adjusted                                        1                1116                  Risk Ratio (M-H, Fixed, 95% CI)       1.64 \[0.89, 3.00\]
  3 Early treatment failures                              1                1103                  Risk Ratio (M-H, Fixed, 95% CI)       0.16 \[0.01, 3.96\]
  4 Parasite clearance time (hours)                       1                1259                  Mean Difference (IV, Fixed, 95% CI)   -2.60 \[-4.94, -0.26\]
  5 Fever clearance time (hours)                          1                1051                  Mean Difference (IV, Fixed, 95% CI)   0.10 \[-1.52, 1.72\]
  6 Gametocyte clearance time (hours)                     1                27                    Mean Difference (IV, Fixed, 95% CI)   -5.40 \[-21.80, 11.00\]
  7 Serious adverse events                                1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       1.00 \[0.25, 3.97\]
  8 Adverse events leading to withdrawal from treatment   1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       0.62 \[0.17, 2.31\]
  9 Patient reported symptoms                             1                7626                  Risk Ratio (M-H, Fixed, 95% CI)       0.99 \[0.80, 1.22\]
  9.1 Vomiting                                            1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       1.00 \[0.45, 2.20\]
  9.2 Diarrhea                                            1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       0.44 \[0.17, 1.14\]
  9.3 Headache                                            1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       1.15 \[0.82, 1.60\]
  9.4 Dizziness                                           1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       0.46 \[0.28, 0.78\]
  9.5 Cough                                               1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       1.50 \[0.74, 3.03\]
  9.6 Myalgia                                             1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       1.39 \[0.83, 2.32\]
  10 Abnormal LFTs; Grade 2 toxicity                      1                                      Risk Ratio (M-H, Fixed, 95% CI)       Totals not selected
  10.1 Alanine aminotransferase (ALT)                     1                                      Risk Ratio (M-H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  10.2 Aspartate aminotransferase (AST)                   1                                      Risk Ratio (M-H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  10.3 Alkaline phosphatase (ALP)                         1                                      Risk Ratio (M-H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  10.4 Bilirubin                                          1                                      Risk Ratio (M-H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  11 Abnormal LFTs; Grade 3 or 4 toxicity                 1                                      Risk Ratio (M-H, Fixed, 95% CI)       Totals not selected
  11.1 Alanine aminotransferase (ALT)                     1                                      Risk Ratio (M-H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  11.2 Aspartate aminotransferase (AST)                   1                                      Risk Ratio (M-H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  11.3 Alkaline phosphatase (ALP)                         1                                      Risk Ratio (M-H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  11.4 Bilirubin                                          1                                      Risk Ratio (M-H, Fixed, 95% CI)       0.0 \[0.0, 0.0\]
  12 Haemoglobin (g/dL)                                   1                                      Mean Difference (IV, Fixed, 95% CI)   Totals not selected
  12.1 Haemoglobin at baseline                            1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  12.2 Haemoglobin day 3                                  1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  12.3 Haemoglobin day 7                                  1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  12.4 Haemoglobin day 28                                 1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  13 Platelet counts (x 10^9^/L)                          1                                      Mean Difference (IV, Fixed, 95% CI)   Totals not selected
  13.1 baseline                                           1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  13.2 day 3                                              1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  13.3 day 7                                              1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  13.4 day 28                                             1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  14 White blood counts (x 10^9^/L)                       1                                      Mean Difference (IV, Fixed, 95% CI)   Totals not selected
  14.1 baseline                                           1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  14.2 day 3                                              1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  14.3 day 7                                              1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  14.4 day 28                                             1                                      Mean Difference (IV, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  15 Abnormal ECG finding                                 1                2542                  Risk Ratio (M-H, Fixed, 95% CI)       0.58 \[0.20, 1.73\]
  15.1 QT prolongation                                    1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       0.17 \[0.02, 1.59\]
  15.2 ECG abnormalities                                  1                1271                  Risk Ratio (M-H, Fixed, 95% CI)       1.00 \[0.25, 3.97\]

Comparison 5. Artesunate-pyronaridine versus artesunate-mefloquine; subgroup analysis
-------------------------------------------------------------------------------------

  Outcome or subgroup title                                      No. of studies   No. of participants   Statistical method                Effect size
  -------------------------------------------------------------- ---------------- --------------------- --------------------------------- ----------------------
  1 Total failure PCR-adjusted (Day 28); subgrouped by region    1                1117                  Risk Ratio (M-H, Fixed, 95% CI)   0.38 \[0.14, 1.03\]
  1.1 East Africa                                                1                38                    Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  1.2 West Africa                                                1                192                   Risk Ratio (M-H, Fixed, 95% CI)   1.48 \[0.06, 35.75\]
  1.3 South central Africa                                       0                0                     Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  1.4 Asia                                                       1                887                   Risk Ratio (M-H, Fixed, 95% CI)   0.31 \[0.10, 0.93\]
  2 Total failure PCR-adjusted (Day 28); subgrouped by country   1                1117                  Risk Ratio (M-H, Fixed, 95% CI)   0.38 \[0.14, 1.03\]
  2.1 Thailand                                                   1                551                   Risk Ratio (M-H, Fixed, 95% CI)   0.12 \[0.03, 0.57\]
  2.2 Vietnam                                                    1                159                   Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  2.3 Cambodia                                                   1                132                   Risk Ratio (M-H, Fixed, 95% CI)   3.31 \[0.17, 62.62\]
  2.4 India                                                      1                45                    Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  2.5 Burkina Faso                                               1                118                   Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]
  2.6 Ivory Coast                                                1                74                    Risk Ratio (M-H, Fixed, 95% CI)   1.65 \[0.07, 39.20\]
  2.7 Tanzania                                                   1                38                    Risk Ratio (M-H, Fixed, 95% CI)   0.0 \[0.0, 0.0\]

Comparison 6. Artesunate-pyronaridine versus artesunate-mefloquine; sensitivity analysis
----------------------------------------------------------------------------------------

  Outcome or subgroup title                                       No. of studies   No. of participants   Statistical method                Effect size
  --------------------------------------------------------------- ---------------- --------------------- --------------------------------- ---------------------
  1 Total failure PCR-unadjusted (Day 28); Sensitivity analysis   1                                      Risk Ratio (M-H, Fixed, 95% CI)   Subtotals only
  1.1 Primary analysis (Cochrane review)                          1                1200                  Risk Ratio (M-H, Fixed, 95% CI)   0.35 \[0.17, 0.73\]
  1.2 Missing data included as failures                           1                1271                  Risk Ratio (M-H, Fixed, 95% CI)   0.72 \[0.49, 1.05\]
  1.3 Missing data included as successes                          1                1271                  Risk Ratio (M-H, Fixed, 95% CI)   0.35 \[0.17, 0.73\]
  1.4 Intention to treat analysis (of trial authors)              1                1271                  Risk Ratio (M-H, Fixed, 95% CI)   0.72 \[0.49, 1.05\]
  1.5 Per-protocol analysis (of trial authors)                    1                1120                  Risk Ratio (M-H, Fixed, 95% CI)   0.36 \[0.17, 0.78\]
  2 Total failure PCR-adjusted (Day 28); Sensitivity analysis     1                                      Risk Ratio (M-H, Fixed, 95% CI)   Subtotals only
  2.1 Primary analysis (Cochrane review)                          1                1187                  Risk Ratio (M-H, Fixed, 95% CI)   0.38 \[0.14, 1.02\]
  2.2 Missing or indeterminate PCR results included as failures   1                1187                  Risk Ratio (M-H, Fixed, 95% CI)   0.38 \[0.14, 1.02\]
  2.3 New infections included as successes                        1                1200                  Risk Ratio (M-H, Fixed, 95% CI)   0.39 \[0.15, 1.03\]
  2.4 Missing data included as failures                           1                1271                  Risk Ratio (M-H, Fixed, 95% CI)   0.82 \[0.54, 1.24\]
  2.5 Missing data included as successes                          1                1271                  Risk Ratio (M-H, Fixed, 95% CI)   0.39 \[0.15, 1.03\]
  2.6 Intention to treat analysis (by trial authors)              1                1271                  Risk Ratio (M-H, Fixed, 95% CI)   0.76 \[0.51, 1.14\]
  2.7 Per-protocol analysis (by trial authors)                    1                1117                  Risk Ratio (M-H, Fixed, 95% CI)   0.37 \[0.13, 1.05\]

Comparison 7. Pyronaridine alone or with artesunate versus another antimalarial: laboratory findings
----------------------------------------------------------------------------------------------------

  Outcome or subgroup title                                    No. of studies   No. of participants   Statistical method                    Effect size
  ------------------------------------------------------------ ---------------- --------------------- ------------------------------------- ------------------------
  1 Abnormal LFTs; Grade 3 or 4 toxicity                       4                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  1.1 Alanine aminotransferase (ALT)                           4                3523                  Risk Ratio (M-H, Fixed, 95% CI)       4.17 \[1.38, 12.62\]
  1.2 Aspartate aminotransferase (AST)                         4                3528                  Risk Ratio (M-H, Fixed, 95% CI)       4.08 \[1.17, 14.26\]
  1.3 Alkaline phosphatase (ALP)                               3                2606                  Risk Ratio (M-H, Fixed, 95% CI)       0.62 \[0.15, 2.51\]
  1.4 Bilirubin                                                3                3067                  Risk Ratio (M-H, Fixed, 95% CI)       1.92 \[0.59, 6.24\]
  2 Combined abnormal LFTs                                     3                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  2.1 ALT = 3 x ULN and Bilirubin = 2 x ULN (Hy\'s Law case)   3                3072                  Risk Ratio (M-H, Fixed, 95% CI)       1.50 \[0.30, 7.42\]
  3 Renal function tests                                       3                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  3.1 Baseline                                                 3                1878                  Mean Difference (IV, Fixed, 95% CI)   -0.12 \[-2.07, 1.84\]
  3.2 Day 3                                                    2                1764                  Mean Difference (IV, Fixed, 95% CI)   -1.72 \[-3.54, 0.10\]
  3.3 Day 7                                                    3                1808                  Mean Difference (IV, Fixed, 95% CI)   -2.76 \[-4.58, -0.94\]
  4 Haemoglobin                                                4                                      Mean Difference (IV, Fixed, 95% CI)   Subtotals only
  4.1 Haemoglobin at baseline                                  4                3534                  Mean Difference (IV, Fixed, 95% CI)   0.08 \[-0.04, 0.21\]
  4.2 Haemoglobin day 3                                        4                3461                  Mean Difference (IV, Fixed, 95% CI)   -0.12 \[-0.20, -0.04\]
  4.3 Haemoglobin day 7                                        4                3394                  Mean Difference (IV, Fixed, 95% CI)   -0.24 \[-0.32, -0.16\]
  4.4 Haemoglobin day 28                                       4                3294                  Mean Difference (IV, Fixed, 95% CI)   -0.09 \[-0.19, 0.01\]
  5 Abnormal ECG findings                                      3                                      Risk Ratio (M-H, Fixed, 95% CI)       Subtotals only
  5.1 ECG abnormalities                                        2                2543                  Risk Ratio (M-H, Fixed, 95% CI)       0.80 \[0.26, 2.43\]
  5.2 QT prolongation                                          3                2991                  Risk Ratio (M-H, Fixed, 95% CI)       0.25 \[0.07, 0.90\]

###### 

Primary outcome measure (Total failure)

  ------------------------------ ------------------------------------------------------------------ ----------------------- ------------------ ----------------------- ----------
  **Analysis^a^**                **Participants**                                                   **PCR^b^-unadjusted**   **PCR-adjusted**                           
  **Numerator**                  **Denominator**                                                    **Numerator**           **Denominator**                            
  Primary analysis               Exclusions after enrolment                                         Excluded^c^             Excluded           Excluded                Excluded
  Missing or indeterminate PCR   Included as failures                                               Included                Excluded           Excluded                
  New infections                 Included as failures                                               Included                Excluded           Excluded                
  Sensitivity analysis 1^d^      As \'Primary analysis\' except: missing or indeterminate PCR       ---                     ---                Included as failures    Included
  Sensitivity analysis 2^e^      As \'Sensitivity analysis 1\' except: new infections               ---                     ---                Included as successes   Included
  Sensitivity analysis 3^f^      As \'Sensitivity analysis 2\' except: exclusions after enrolment   Included as failures    Included           Included as failures    Included
  Sensitivity analysis 4^g^      As \'Sensitivity analysis 2\' except: exclusions after enrolment   Included as successes   Included           Included as successes   Included
  ------------------------------ ------------------------------------------------------------------ ----------------------- ------------------ ----------------------- ----------

^a^Note: we removed participants that did not satisfy the inclusion criteria after randomization from all calculations.

^b^PCR: polymerase chain reaction.

^c^\'Excluded\' means removed from the calculation.

^d^To re-classify all indeterminate or missing PCR results as treatment failures in the PCR-adjusted analysis.

^e^To re-classify all PCR-confirmed new infections as treatment successes in the PCR-adjusted analysis. (This analysis may overestimate efficacy as PCR is not wholly reliable and some recrudescences may be falsely classified as new infections. Also some participants may have gone on to develop a recrudescence after the new infection).

^f^To re-classify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment failures. For PCR-unadjusted total failure this represents a true worse-case scenario.

^g^To re-classify all exclusions after enrolment (losses to follow-up, withdrawn consent, other antimalarial use, or failure to complete treatment) as treatment successes.

###### 

Adverse events risk of bias assessment methods

  ------------------------------------------------------------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Criterion**                                                       **Assessment**   **Explanation**

  **Patient-reported symptoms**                                                        

  Was **monitoring** active or passive?\                              Active\          We classified monitoring as \'active\' when authors reviewed participants at set timepoints and enquired about symptoms.
                                                                      Passive\         
                                                                      Unclear          

  Was **blinding** for participants and outcome assessors adequate?   Adequate\        We classified blinding as \'adequate\' when both participants and outcome assessors were blinded to the intervention group, and the methods of blinding (including use of a placebo) were described.
                                                                      Inadequate\      
                                                                      Unclear          

  Was **outcome data reporting** complete or incomplete?              Complete\        We classified outcome data reporting as \'complete\' when data was presented for all the time-points where it was collected.
                                                                      Incomplete\      
                                                                      Unclear          

  Were all **participants included** in reporting?                                     We report the percentage of randomized participants included in adverse event reporting.

  Was the**analysis independent** of study sponsor?                   Yes\             We classified the analysis of trials sponsored by pharmaceutical companies as independent of the sponsor when it was clearly stated that the sponsor had no input to the trial analysis
                                                                      No\              
                                                                      Unclear          

  **Laboratory tests**                                                                 

  **Number of tests undertaken**                                      ---              We extracted the type and number of laboratory tests were taken.

  **Timing of tests**\                                                Adequate\        We classified the number and timing of tests as \'adequate\', when tests were taken at baseline, plus two other timepoints within the first week after treatment, plus the last day of the study. We classed the number of test taken as \"inadequate\", if either the laboratory controls in the first week or controls at four weeks were not performed.
  Was number and timing of tests adequate?                            Inadequate       

  **Reporting of test results**\                                      Complete\        We classified reporting as \'complete\' when test results of all time points were reported. For the trials with inadequate number of tests taken, we considered completeness of reporting as inconsequential, and therefore did not record a judgement.
  Was reporting of test results complete?                             Incomplete       

  **Independence of data analysis**\                                  Yes\             We classified the analysis of trials sponsored by pharmaceutical companies as independent of the sponsor when it was clearly stated that the sponsor had no input to the trial analysis
  Was data analysis independent?                                      No\              
                                                                      Unclear          
  ------------------------------------------------------------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Dosing regimens of artesunate-pyronaridine

  ---------------- --------------------------- ------------------------------ ---------------------------- ------------ -------------
  **Trial ID**     **Actual or target dose**   **Intervention(mg/kg/dose)**   **Comparator(mg/kg/dose)**                
  **Artesunate**   **Pyronaridine**            **Artemisinin-derivative**     **Partner drug**                          
  [@b1]            Actual dose                 2.2 to 4.4                     6.7 to 13.3                  1.3 to 4.0   8.0 to 24.0
  [@b6]            Target dose                 2.4 to 4.6                     7.2 to 13.8                  NS           NS
  [@b5]            Actual dose                 2.4 to 4.7                     7.1 to 14.0                  2.5 to 5.0   6.2 to 12.5
  [@b2]            Target dose                 2.4 to 4.6                     7.2 to 13.8                  ---          10, 5, 5
  [@b3]            Target dose                 ---                            16, 8, 8                     ---          10, 5, 5
  [@b4]            Target dose                 ---                            8, 8, 8, 8                   ---          10, 10, 5
  ---------------- --------------------------- ------------------------------ ---------------------------- ------------ -------------

NS = Not specified.

###### 

Risk of bias for patient reported symptoms

  ------------------------- ----------------------------------- ------------------------------- ------------------------ ------------------------------------------------ -------------------------------- ------------- --------- --------- -----
  **Trial ID**              **Monitoring active or passive?**   **Outcome data reporting**      **Blinding adequate?**   **% of participants included in AE reporting**   **Independent data analysis **                                     
  **Days data collected**   **Days data reported**              **Patient**                     **Clinician**            **Data analysis**                                **AS-Pyr**                       **Control**                       
  [@b6]                     Unclear                             0 to 3, 7, 14, 21, 28, 35, 42   Unclear                  Yes                                              Yes                              Unclear       100%      100%      No
  [@b1]                     Unclear                             Unclear                         Unclear                  No                                               No                               Yes           100%      100%      No
  [@b5]                     Unclear                             Unclear                         Unclear                  No                                               No                               Unclear       100%      100%      No
  [@b2]                     Unclear                             Unclear                         Unclear                  Yes                                              Yes                              Yes           100%      100%      Yes
  [@b3]                     Unclear                             Unclear                         Unclear                  No                                               No                               Unclear       Unclear   Unclear   Yes
  [@b4]                     Unclear                             Unclear                         Unclear                  No                                               No                               Unclear       100%      100%      Yes
  ------------------------- ----------------------------------- ------------------------------- ------------------------ ------------------------------------------------ -------------------------------- ------------- --------- --------- -----

###### 

Risk of bias table for biochemical liver function tests

  -------------- --------------------- ----------------- --------------------- ----------------------------- ---------------------------------------------------- -------------------------------------------
  **Trial ID**   **Number of tests**   **Days tested**   **Days reported  **   **Days tested adequate?  **   **For adequate testing, was reporting complete? **   **Data analysis independent of sponsor?**
  [@b6]          4^1^                  0, 3, 7, 28^2^    3, 7, 28              Adequate                      Complete                                             No
  [@b1]          4^1^                  0, 3, 7, 28, 42   3, 7                  Adequate                      Incomplete ^3^                                       No
  [@b5]          4^1^                  0, 28, 42         0, "post baseline"    Inadequate                    \-^4^                                                No
  [@b2]          4^1^                  0, 3, 7, 28^2^    3, 7, 28              Adequate                      Complete                                             Yes
  [@b3]          4^1^                  0, 7              0, 7                  Inadequate                    ---                                                  Yes
  [@b4]          5^1,5^                0, 7              0, 7                  Inadequate                    ---                                                  Yes
  -------------- --------------------- ----------------- --------------------- ----------------------------- ---------------------------------------------------- -------------------------------------------

^1^ Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TBIL).

^2^ Plus day 42 if clinically indicated.

^3^ Does not report the outcome data for day 28 in additional file 3.

^4 ^The trial did not report ALP values for all participants (ALT and AST values for 848 patients in the artesunate pyronaridine arm and for 423 participants in the artesunate mefloquine arm at baseline; AST values only for 635 participants and 308 participants respectively at baseline).

^5^ Plus conjugated bilirubin in addition.

###### 

Additional data from Kayentao 2012

  ------------------------------------------------------- -------------------------------- --------------------------------- ----------------------------- -------------
  **Trial ID**                                            **Outcome**                      **Artesunate-pyronaridine**       **Artemether-lumefantrine**   **P value**

  [@b1]                                                   Median parasite clearance time   24.1 hours(95% CI 24.0 to 24.1)   24.2 hours\                   0.02
                                                                                                                             (95% CI 24.1 to 32.0)         

  Median fever clearance time                             8.1 hours(95% CI 8.0 to 8.1)     8.1 hours(95% CI 8.0 to 15.8)     0.049                         

  \"Post-baseline gametocytes\"                           95/354\                          44/178(24.7%)                     0.6                           
                                                          (26.8%)                                                                                          

  Gametocyte development(in those negative at baseline)   53/354(15%)                      20/178(11.2%)                     0.24                          
  ------------------------------------------------------- -------------------------------- --------------------------------- ----------------------------- -------------

###### 

Summary of ECG monitoring and results

  ---------------------- --------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  **Trial ID  **         **Days tested**       **ECG results **                                                                                                                                                            

  **Pyronaridine arm**   **Comparator arm**                                                                                                                                                                                

  [@b1]                  0, 2,\                \"no post baseline clinically important ECG results\"                                                                                                                       \"no post baseline clinically important ECG results\"
                         7, 14, and 28                                                                                                                                                                                     

  [@b6]                  0, 2, 7, 14, and 28   1 patient with T-wave inversion at day 2\                                                                                                                                   1 patient with sinus bradycardia and sinus arrhythmia on day 2\
                                               1 patient with ventricular premature complexes and extended QTc (manual reading QTcB 461 ms, QTcF 458 ms) at day 21                                                         1 patient with sinus bradycardia on day 2

  [@b5]                  Unclear               6/848 (0.7%) patients with abnormal ECGs- \"All were mild and resolved before study completion\"1/848 with QT prolongation- None had a QT interval that exceeded 480 msec   3/423 (0.7%) patients with abnormal ECGs - \"All were mild and resolved before study completion\"\
                                                                                                                                                                                                                           3/423 with long or prolonged QT interval - None had a QT interval that exceeded 480 msec

  [@b2]                  0, 2, 7,\             1/226 (0.4%) patients with QTc prolongations                                                                                                                                6/222 (2.7%) patients with QTc prolongations (1/222 not drug-related)
                         14, and 42                                                                                                                                                                                        
  ---------------------- --------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
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